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General introduction  
Aim and outline of this thesis
Intra-uterine tissue engineering of full thickness skin 
defects in a fetal sheep model
Human amniotic fluid derived cells can competently 
substitute dermal  fibroblasts in a tissue-engineered 
dermo-epidermal skin analog
Human amniotic fluid-derived cells from fetuses with 
a neural tube defect do not deposit collagen type I 
protein
Cell plasticity in wound healing: paracrine factors of  
M1/ M2 polarized macrophages influence the 
phenotypical state of dermal fibroblasts 
Epithelial-to-mesenchymal transition in fibrosis: 
Collagen type I expression is highly upregulated after 
EMT, but does not contribute to collagen deposition



















Spina bifida is a type of neural tube defect and is one of the most common 
birth defects. It has an average worldwide incidence of approximately 1 in 
2000 live births [1;2]. Spina bifida is caused by the failure of the neural 
tube to close at the end of the first month of embryonic development. 
There are three types of spina bifida; spina bifida occulta, meningocele 
and myelomeningocele. Spina bifida occulta is the mildest form, which 
often remains undetected. A meningocele, a moderate form of spina 
bifida, is characterized by the extrusion of the spinal cord into a sac filled 
with cerebrospinal fluid. Meningoceles are usually covered by normal skin. 
The most severe and frequent form of spina bifida is myelomeningocele 
(MMC), an open defect in which either meninges or neural tissue is exposed 
to the amniotic fluid during pregnancy. Children with MMC suffer from 
severe lifelong disabilities, such as hydrocephalus, mental impairment, 
paraplegia, urinary and faecal incontinence and skeletal deformities.
The etiology of spina bifida is multifactorial; both environmental and 
genetic factors play a role[3]. In less than ten percent of children with spina 
bifida, chromosomal abnormalities, single-gene mutations or teratogenic 
causes are identified [4;5]. In most cases the underlying cause of spina bifida is 
unknown. However, inadequate intake of folic acid, before and during early 
pregnancy, is associated with an increased risk of spina bifida. Case control 
studies, randomized clinical trials, and community based interventions 
with vitamin supplements have shown that folic acid deficiency increases 





underlying the protective effect of folic acid has not yet been established. 
Spina bifida can be diagnosed during the first and second trimester of 
pregnancy using ultrasound and maternal serum fetoprotein tests[7]. Positive 
findings of these screening methods can be followed by amniocentesis 
to examine the fetal karyotype to rule out chromosomal anomalies. 
Furthermore, amniotic fluid α-fetoprotein and acetylcholinesterase 
concentrations can be used to discriminate between open ventral wall 
defects and open neural tube defects [8]. 
Treatment of MMC consists of surgical closure of the spinal lesion 
within 48h after birth (postnatal surgery), to prevent infection and 
further damage to the spinal cord. If there are signs of hydrocephalus, a 
cerebral shunt is placed at the same time as the lesion is closed. Postnatal 
surgery prevents further neurological deterioration, but does not improve 
neurological damage. This neurological damage in spina bifida is caused 
by two hits. The first ‘hit’ is the failure of the neural tube to close during 
the embryonic period and the second ’hit’ is the exposure of the neural 
tissue to the intrauterine environment leading to secondary neural tissue 
damage [9;10]. It is thought that this secondary damage is caused by the 
amniotic fluid. A study has shown that human amniotic fluid from late 
gestation indeed has a toxic effect on rat neural tissue [11], which might be 
explained by the presence of inflammatory factors during late gestation, 
including increased levels of urea, tissue factor, vernix, TGF-β and 
gastrointestinal waste products [12]. The presence of meconium [13;14] and 
digestive enzymes[15] have been associated with neural tissue damage in 
experimental spina bifida models.
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To prevent secondary neural damage caused by the exposure to the 
amniotic fluid during pregnancy, intra-uterine closure of the defect could 
be performed. Different research groups using spina bifida animal models 
showed an improved neurological outcome after fetal closure of the 
defect [9;10;16-19]. Following these successful outcomes in animal models, a 
randomized trial, called the MOMS (Management Of Myelomeningocele) 
trial, has been performed from 2003 till 2010 in the USA [20]. This 
randomized trial, including 183 patients, compared two different 
treatment methods for spina bifida: fetal surgery between the 19th and 
25th week of gestation and the standard postnatal repair. This clinical trial 
demonstrated that open fetal surgery for spina bifida (by closing the defect 
with skin) reduced the risk of death and the need for shunting before 
12 months and improved mental development and motor function at 30 
months as compared to postnatal surgery. However, prenatal surgery was 
also associated with higher rates of preterm birth (average gestational age 
of 34.1 weeks compared to an average of 37.3 weeks for postnatal surgery) 
and uterine scar defects.
Tissue engineering 
Spina bifida occurs in different degrees and when the defect is very 
large it may not be possible to close the defect in utero with skin. In those 
cases, a tissue engineered construct might represent a solution to acquire 
skin coverage over the defect. This approach may also make endoscopic 
treatment possible. Endoscopic treatment is less invasive for the mother 






In general, a tissue engineered construct consists of a three dimensional 
scaffold that can replace and repair damaged or lost tissue. Scaffolds can be 
made of naturally occurring materials or, alternatively, synthetic materials, 
and are designed to mimic the extracellular matrix (ECM) of the tissue 
that it replaces. Scaffolds to be used for the purpose to cover the spina 
bifida lesions should be biodegradable, impermeable (to avoid leakage of 
amniotic fluid into the lesion), have an appropriate mechanical strength, 
support cellular ingrowth and angiogenesis and reduce scar formation. 
The therapeutic potential of tissue engineering for prenatal neural tube 
coverage has been demonstrated using a variety of different materials, 
including natural materials [21-24], synthetic materials [25;26], and growth 
factor-loaded scaffolds [27].  The addition of growth factors to scaffolds 
can improve tissue regeneration, by stimulating cellular ingrowth and/
or angiogenesis, or by reducing wound contraction. Another option to 
stimulate tissue regeneration is the addition of cells to the scaffold. For 
fetal tissue engineering, the amniotic fluid is an attractive cell source. 
Diagnostic amniocentesis is routinely offered to a mother with a fetus 
in whom a structural anomaly, such as spina bifida, has been diagnosed 
by prenatal imaging. Amniocentesis is associated with a very low rate of 
spontaneous abortion of only 0,5%[28]. Interestingly, cells can easily be 
harvested from the amniotic fluid [29]. From 5 ml of amniotic fluid, more 
than 100 x 106 cells can be expanded, which can be used to engineer a 
surgically implantable construct [30].
14
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Amniotic fluid cells 
Amniotic fluid contains different cell types derived from all three germ 
layers, including mesenchymal, hematopoietic, epithelial and trophoblastic 
cells [31]. These cells derive from the developing fetus (fetal skin and digestive 
tract) and from the inner surface of the amniotic membrane. 
In 2003 the first evidence that human amniotic fluid contains stem 
cells was provided by different groups. In ‘t Anker et al. demonstrated that 
human amniotic fluid contains a cell population positive for mesenchymal 
markers CD73, CD90, CD105 and CD166, but negative for hematopoietic 
markers CD14, CD34 and CD45. This mesenchymal cell population 
was able to differentiate into different mesenchymal (adipogenic and 
osteogenic) lineages, suggesting that these mesenchymal cells had stem cell 
properties [32]. Furthermore, Prusa et al. showed that the amniotic fluid 
contains a population of cells that express the transcription factor Oct-4, 
which is a marker for pluripotent human stem cells known to be expressed 
by embryonic stem cells [33]. In 2004, a study showed the existence of a cell 
population (CD44+CD105+OCT4+) within the amniotic fluid which had 
the potential to differentiate into adipocytes and osteoblasts [34]. In 2007, 
De Coppi et al. showed that human amniotic fluid stem cells (HAFSCs) 
could be cultured for up to 250 population doublings with a normal 
karyotype and induced to differentiate into cell types of all three germ layers, 
including adipogenic, osteogenic, myogenic , endothelial, neurogenic and 
hepatic lineages [35]. HAFSCs secrete various cytokines and chemokines 
that are involved in wound healing, such as IL-6, IL-8, TGF-β, VEGF and 





a stimulatory effect on dermal fibroblasts in vitro, suggesting that these 
cells might be beneficial in the treatment of skin wounds [36]. In summary, 
mesenchymal cells from the amniotic fluid express several markers for 
embryonic stem cells and adult mesenchymal stem cells, and have a higher 
proliferation potential and broader differentiation capacity compared to 
adult stem cells. Taken together, these data suggest that amniotic fluid stem 
cells represent a class of stem cells that is intermediate between embryonic 
and adult stem cells [31]. An important advantage of human amniotic fluid 
cells is that, unlike embryonic stem cells, these cells do not form tumours 
in immune-deficient mice [35].  
Over the past decade, HAFCs have successfully been used in experimental 
animal models for the treatment of a wide variety of congenital anomalies 
diagnosed either in utero or postnatally. Fauza et al. have used sheep AFCs 
to construct tendon grafts for the repair of diaphragmatic hernia [37-39]. To 
repair congenital chest wall and craniofacial defects, tissue engineered bone 
constructs with AFCs have been developed [40-42]. Furthermore, functional 
tracheal repair using tissue-engineered cartilage has been demonstrated 
in a fetal sheep model [43;44] and AFCs have been used to fabricate tissue 
engineered heart valves [45;46]. 
Adult and fetal wound healing
To study the effects of a tissue engineered construct in vivo, knowledge 
about normal wound healing is important. 
Adult wound healing occurs in three, in time overlapping, phases: 
inflammation, tissue repair and tissue maturation [47;48]. The primary cell 
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types involved in the inflammatory phase are platelets, neutrophils and 
monocytes/macrophages. The inflammatory phase starts right after tissue 
damage with the generation of a fibrin-rich clot by blood coagulation 
and platelet aggregation. Activated platelets release several growth factors 
that attract neutrophils to the wound. Neutrophils enter the wound site 
to clean the wounded area from cell debris and foreign materials such as 
bacteria. After 2-3 days, monocytes are recruited to the wound area and 
differentiate into macrophages. The tissue formation phase starts 2-10 days 
after injury with the migration of keratinocytes over the damaged dermal 
tissue. Macrophages provide a source of cytokines that stimulate fibroblast 
proliferation and angiogenesis. A part of these fibroblasts differentiate 
into myofibroblasts, these cells produce new ECM, called granulation 
tissue, and cause contraction of the wound edges. This granulation tissue 
is necessary to support cellular ingrowth and forms the new substrate for 
keratinocyte migration. The last stage of wound healing, the maturation 
phase, begins 2-3 weeks after injury and can prolong for more than one 
year. During this phase, most cells undergo apoptosis or exit the wound 
site. The remaining matrix consists mainly of collagen type III and is 
actively remodelled to a matrix composed of collagen type I. This collagen 
remodelling is controlled by matrix metalloproteinases that are produced 
by fibroblasts, macrophages and endothelial cells. Nevertheless, wounds 
fail to regain the same (breaking) strength as normal skin, a scar can have 
a maximum strength of 70% compared to the uninjured skin [47]. Fibrosis 
can be a consequence of inappropriate tissue remodelling resulting in 





degradation, thereby causing damage to the tissue and diminishing its 
function. 
A major difference between adult and fetal wound healing is that fetal 
wound healing is scarless, depending on the size of the wound (large fetal 
wounds do not repair scar free) and gestational age (only scarless healing in 
fetuses <24 weeks of gestation) [49;50]. The exact mechanism of fetal scarless 
healing is poorly understood, but it is known that the fetal environment 
(amniotic fluid) does not play a crucial role. It has been shown that injured 
adult skin transplanted into fetal lambs (fetal environment) continued to 
heal with scarring [51] and when injured fetal skin was implanted into adult 
nude rats, the wounds repair without scar formation [50].  
A number of growth factors have different expression patterns in fetal 
wound healing compared to adult wound healing. For example, increased 
expression levels were found during fetal healing for platelet derived growth 
factor (PDGF; involved in fibroblast migration and proliferation) [51], 
fibroblast growth factor-2 (FGF2; involved in fibroblast proliferation and 
migration and angiogenesis) [52] and tumor growth factor-beta 3 (TGF-β3; 
anti-scarring effect) [53;54]. The addition of exogenous TGF-β3 improved 
wound healing with less scar formation in animal models and a human 
clinical study [55;56]. Several growth factors that play a role in inflammation 
and fibrosis, including interleukin (IL)-6, IL-8 [57;58], cyclo-oxygenase-2 
(COX-2) and prostaglandin E2 (PGE2) [59] and tumor growth factor beta-1 
(TGF-β1) [54;60], are lower expressed in fetal wound healing compared to 
adult wound healing. In addition to variations in growth factor expression 
levels, the composition of the ECM in fetal wounds is different compared 
18
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to adult wounds. 
It has been demonstrated that fetal wounds have increased levels of 
hyaluronic acid (a glycosaminoglycan) compared to adult wounds [61;62] and 
that exogenous addition of hyaluronic acid reduces the formation of scar 
tissue in adults [63]. Furthermore, fetal and adult wounds show differences 
in collagen synthesis. Fetal fibroblasts express higher levels of collagen III 
and the new collagen that has been deposited have thinner collagen fibers 
and are arranged in the same ‘organized’ pattern as in uninjured skin [64;65]. 
It has been suggested that collagen deposited by fetuses is less mature with 
less cross-linking [66] which might be due to the lower expression levels 
of lysyl oxidase, which is known to play a role in collagen cross-linking 
[67]. Turnover of the extracellular matrix may also be an important 
component of scarless healing. Matrix metalloproteinases (MMPs) and 
their inhibitors (tissue-derived inhibitors of metalloproteinases (TIMPs)) 
regulate remodelling of the extracellular matrix. Higher levels of MMPs, 
in combination with lower levels of TIMPs, were found in fetal wounds, 
resulting in more degradation compared to matrix deposition [68].
Aim & outline of this thesis
The main objective of this thesis is to gain more insight into cellular 
processes involved in fetal and adult tissue repair. Such knowledge will be 
useful for the design of novel therapies with regard to e.g. spina bifida.
In chapters 2, 3 and 4, we investigated several options to improve fetal 
tissue engineering in the treatment of spina bifida. In chapter 2, we used 





skin defect model in fetal sheep. We showed that collagen type I scaffolds 
can be used for the treatment of such defects and that fetal wound healing 
can be improved by the addition of the growth factors FGF-2 and VEGF, 
leading to a better epidermialization, more blood vessel formation and 
formation of skin appendages, indicating less scar formation. Although 
the results of the addition of growth factors to scaffolds are promising, it is 
unknown what the long-term effects of these growth factors are and what 
the optimal loading of these growth factors is (in this study the maximum 
loading capacity was used). In chapter 3, we investigated whether 
amniotic fluid-derived cells can be used instead of growth factors. These 
cells produce a variety of growth factors in physiological levels as well as 
extracellular matrix proteins. In a tissue engineered dermo-epidermal skin 
analog used in a humanized rat model we showed that amniotic fluid cells 
from healthy fetuses can be used to repair skin defects. For future therapy 
it is important that autologous cells are used to prevent immunological 
complications. However, it is not known what the characteristics are of 
amniotic fluid-derived stem cells that are derived from fetuses with a 
neural tube defect. In chapter 4, we found that neural tube defect (NTD) 
amniotic fluid cells (AFCs) behave differently compared to AFCs derived 
from healthy fetuses. In contrast to healthy AFCs, NTD-AFCs do not 
deposit collagen type I. This is a disadvantage when these cells are used for 
fetal tissue engineering. Further in vivo experiments have to be carried out 
to conclude whether these cells are suitable for this purpose or not.    
In wound healing as well as in tissue engineering the role of paracrine 
communication between fibroblasts and macrophages likely plays an 
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important role. In chapter 5, we investigated the role of paracrine factors 
of classically activated (M1) and alternatively activated (M2) macrophages 
on dermal fibroblasts. One of the findings in our study was that secreted 
factors from M1-polarized macrophages induced pro-inflammatory and 
extracellular matrix degrading fibroblasts, a phenotype that could be 
reversed by conditioned medium derived from M2-polarized macrophages. 
This implies that fibroblasts (e.g. in wound healing) show a high dynamic 
plasticity, which is regulated by macrophages.
An important aspect in tissue engineering is the formation of newly 
synthesized extracellular matrix proteins. However, when too much 
collagen is deposited, this could lead to fibrosis. Transdifferentiation of 
epithelial cells into mesenchymal cells is an event that may lead to fibrosis. 
In chapter 6, we investigated in an in vitro model whether transdifferenti-
ated epithelial cells produce collagens in significant amounts. In this study 
we found that transdifferentiated kidney and lung epithelial cells produce 
much lower amounts of collagen type I compared to myofibroblasts, 
suggesting that the direct contribution of the epithelium to fibrosis is 
minor. 
Finally, in chapter 7, the results of the research presented in this thesis 
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In spina bifida the neural tube fails to close during the embryonic period 
and it is thought that prolonged exposure of the unprotected spinal cord 
to the amniotic fluid during pregnancy causes additional neural damage. 
Intra-uterine repair might protect the neural tissue from exposure to 
amniotic fluid and might reduce additional neural damage. Biodegradable 
collagen scaffolds may be useful in case of fetal therapy for spina bifida, 
but biochemical properties need to be studied. The aim of this study was 
to investigate whether biodegradable collagen scaffolds can be used to treat 
full-thickness fetal skin defects. We hypothesized that the pro-angiogenic 
growth factors VEGF and FGF2 would enhance vascularization, 
epidermialization and lead to improved wound healing. To investigate the 
effect of these two growth factors, a fetal sheep model for skin defects was 
used. Compared to wounds treated with bare collagen scaffolds, wounds 
treated with growth factor-loaded scaffolds showed excessive formation of 
capillaries and less myofibroblasts were present in these wounds, leading 
to less contraction. This study has demonstrated that collagen scaffolds 
can be used to treat fetal skin defects and that the combination of collagen 
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Introduction
There are different congenital structural anomalies in which closure 
of skin and underlying structures does not occur during embryonic 
development. In spina bifida (incidence rate 1 of every 2,000 live births) 
the neural tube fails to close during the embryonic period and it is thought 
that exposure of the neural tube to the amniotic fluid during pregnancy 
causes additional neural damage (second hit hypothesis) [1]. Current 
treatment of spina bifida consists of surgical closure of the defect in the 
early postnatal period, in order to prevent infection and further damage. 
However, the damage caused by the exposure to the amniotic fluid is 
irreversible. 
It is expected that intra-uterine repair of the defect diminishes the 
damage caused by exposure to amniotic fluid. An additional advantage of 
such a fetal intervention is that fetal tissue can regenerate, instead of repair 
with fibrosis [2]. During the first and second trimester of development, fetal 
skin wounds heal with a normal epidermal and dermal architecture. During 
the third trimester a transition from scarless repair to fibrotic repair occurs, 
which is comparable to adult wound healing with more inflammation and 
fibrosis [2]. However, the ability of the fetus to heal full-thickness wounds 
without fibrosis depends on the size of the defect, independent of the 
gestational age [3].
The aim of this study was to investigate whether biodegradable collagen 
scaffolds can be used to treat full-thickness fetal skin defects to allow in 
situ fetal dermal repair and epidermal overgrowth. For this purpose we 
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developed a fetal skin defect model in sheep, and treated the defects with 
a crosslinked type I collagen scaffold (which was previously applied in a 
rat model and sheep model [4-7]). Collagen scaffolds can be modulated in 
different ways to enhance and regulate wound healing. The porous matrix 
structure can be varied and growth factors can be incorporated to promote 
angiogenesis and cellular ingrowth. In this study we used a collagen scaffold 
and a collagen scaffold loaded with heparin and two growth factors: vascular 
endothelial growth factor (VEGF) and basic fibroblast growth factor 
(FGF2). Heparin was used for optimal growth factor binding. VEGF is a 
40- to 45-kDa homodimeric glycoprotein promoting angiogenesis[8]. FGF2 
can also act as angiogenic factor by directing endothelial cell migration 
and proliferation. The combination of VEGF and FGF2 has been reported 
to have potent synergistic effects on neovascularization both in in vitro 
and in vivo experiments [9-12]. Furthermore, FGF2 reduces scar formation 
when exogenously applied to the wound site [13] and diminishes wound 
contraction, when used in combination with a collagen matrix [14]. FGF2 
can also act as a potent mitogen for fibroblasts and keratinocytes[15;16], 
indicating an effect on both dermal as well as epidermal healing. With the 
stimulation of vascular ingrowth and cellular infiltration, regeneration of 
tissue can be improved by supplying sufficient oxygen and nutrients. By 
regulating the host response to the scaffold in this way, formation of excess 
scar formation may be prevented.
We evaluated fetal wound healing and closure of full thickness skin 
wounds by means of intra-uterine tissue engineering using type I collagen 
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and FGF2 (COL-HEP/VF), and compared these with untreated defects 
2, 4 and 8 weeks after fetal surgery. Cellular ingrowth, vascularization, 
scar tissue formation and degradation of the scaffolds were evaluated by 
histology and immunohistochemistry.
Materials and methods
The study has been approved by the local Ethics Committee on Animal 
Research of the Radboud University Nijmegen, the Netherlands (RU-DEC 
2007-239).
Preparation of collagen scaffolds
Type I collagen was purified from bovine achilles tendon as described 
previously [17;18]. To prepare collagen scaffolds, a 0.67% (w/v) type I 
collagen suspension in 0.25 M acetic acid was shaken overnight at 4°C and 
homogenized on ice using a Potter-Elvehjem homogenizer (Louwers Glass 
and Ceramic Technologies, Hapert, The Netherlands). Air bubbles were 
removed by centrifugation at 100 g for 15 min at 4°C. The suspension 
was then poured into 6-well plates (4 ml per well), frozen at -20°C, and 
lyophilized. Scaffolds were pre-incubated with 50 mM 2-morpholinoethane 
sulfonic acid (MES) pH 5.0 containing 40% ethanol for 30 min at 22°C. 
After removal of this solution, scaffolds were crosslinked using 33 mM 
1-ethyl-3-(3-dimethyl aminopropyl) carbodiimide (EDC) and 6 mM 
N-hydroxysuccinimide (NHS) in 50 mM MES pH 5.0 containing 40% 
ethanol for 4 h at 22°C in the presence or absence of 0.25% heparin 
(Diosynth, Oss, The Netherlands). Scaffolds were then washed, frozen and 
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lyophilized. Scaffolds were disinfected in 70% ethanol (6x 7 ml per well) 
followed by washings with sterile PBS (8 x 7 ml per well). The crosslinked 
type I collagen scaffold is abbreviated in the text as COL.
The growth factors vascular endothelial growth factor 165 (VEGF; 
human recombinant, R&D Systems, Minneapolis, MN, USA) and basic 
fibroblast growth factor 2 (FGF2; human recombinant, R&D Systems) 
were loaded onto the heparin-crosslinked collagen scaffolds by incubating 
six Ø 12 mm scaffolds in 5 ml PBS containing 3.5 µg/ml VEGF and 3.5 
µg/ml FGF2, followed by 3 washings with the same volume of PBS. This 
scaffold is abbreviated in the text as COL-HEP/VF.
Analysis of collagen scaffolds
The ultrastructure of the scaffolds was visualized by scanning electron 
microscopy (SEM). Specimens were mounted on stubs, sputtered with an 
ultrathin layer of gold in a Polaron E5100 coating system and visualized 
with a JEOL JSM-6310 SEM apparatus operating at 15 kV.
The degree of crosslinking of the scaffolds was determined 
spectrophotometrically by determining the amine group content using 
2,4,6-trinitrobenzene sulfonic acid. Crosslinking efficiency was expressed 
as the percentage of the total number of amine groups that were used in 
the crosslinking process[19;20]. 
The heparin content of the films was determined applying a 
hexosamine assay using p-dimethylamino-benzaldehyde, taking heparin 
as a standard[21;22].
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with sodium dodecyl sulfate polyacrylamide gel electrophoresis 
(SDS-PAGE) on a 15% (w/v) gel, followed by silver staining using a 0.1% 
(w/v) AgNO3 solution. COL-HEP scaffolds incubated with growth factors 
and a standard curve of 0-100 ng of either VEGF of FGF2 were incubated 
for 15 min in a boiling water bath under reducing conditions using 5% 
(v/v) 2-mercaptoethanol. The intensity of the bands was analyzed using 
Adobe Photoshop. 
The location of growth factors in the scaffolds was visualized by 
immunohistochemistry using the ABC method [23] with antibodies 
HS4C3[24], goat anti-human VEGF (Sigma Chemical Co., St Louis, MO, 
USA) and rabbit anti-bovine FGF2 (R&D Systems, Minneapolis, MN, 
USA).
Animals and surgical procedures
Nine pregnant ewes of Dutch Texel breed underwent surgery at 79 
days’ gestation (term, 140-147 days). For sedation, the animals were 
pre-medicated with an intramuscular injection of midazolam (0.5 mg/kg). 
Anesthesia for surgery was induced by an intravenous injection of propofol 
(5 mg/kg) followed by tracheal intubation. The ewes were maintained on 
general anesthesia with 1.5% isoflurane. For analgesia, flunixin (2 mg/
kg) and sufentanil (4 µg/kg) were given intravenously followed by a 
maintenance dosage sufentanil of 2 µg/kg/h. Heart rate, temperature, 
oxygen saturation and carbon dioxide concentration of the expired air 
were monitored. Fetal anesthesia was achieved by transplacental passage 
of the medications, administered to the ewe. The abdomen was shaved, 
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cleaned and aseptically prepared. After a low midline laparotomy under 
sterile conditions, the uterus was inspected for the number of fetuses. 
One uterus horn was exteriorized, wrapped in gauzes soaked with warm 
phosphate buffered saline (PBS), and the position of the fetal lamb was 
determined by palpation. At a favorable location over the caudal side of 
the fetus a hysterotomy was made.
Three circular skin lesions, 12 mm in diameter, were made on the back 
of the fetus by excising the skin. The lesion on the left side was covered 
with a collagen scaffold (COL). The lesion on the right side was covered 
with the collagen-heparin scaffold with VEGF and FGF2 (COL-HEP/
VF). The applied scaffolds were slightly thicker than the removed skin. 
The lesion in the middle of the back remained uncovered. The scaffolds 
were secured and marked with four 6-0 prolene (Ethicon, Somerville, NJ, 
USA) interrupted sutures around the skin lesion. After surgery the fetus 
was replaced in the uterus and the amniotic fluid volume was restored 
with warm PBS solution. Amoxicillin (250 mg) was added to the amniotic 
fluid. The uterus was closed with a running suture in 2 layers using 2-0 
vicryl (Ethicon, Somerville, NJ, USA). In case of twin pregnancy the same 
procedure was performed using the techniques as described above. Sodium 
penicillin (1,000,000 IU) was administered to the intra-abdominal space 
and the abdominal wall was closed in 3 layers using EP6 Serafil for the 
fascia, 2-0 Vicryl for the subcutaneous tissue and 1-0 Vicryl Plus for the 
skin. Depomycin (20,000 IU penicillin ml-1, 200 mg streptomycin ml-1) 
was initiated preoperatively (0.6 ml/10 kg) and maintained postoperative-
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(10 µg/kg, intravenous) and flunixin (2 mg/kg, intramuscular) were given 
for three days to provide postoperative analgesia. The ewes returned to the 
farm soon after they were able to stand.
Macroscopic evaluation
The animals were sacrificed at three time points. Evaluation took 
place at 93 days’ gestation (2 weeks post surgery), 107 days’ gestation (4 
weeks post surgery) and 140 days’ gestation (term) in group 1, 2 and 3 
respectively. Ewes and fetal lambs were euthanized by 10 ml intravenously 
and 5 ml intracardiacally injected T61® (200 mg embutramide ml-1, 50 mg 
mebezoniumjodide ml-1 and 5 mg tetracainhydrochloride ml-1; Intervet, 
Boxmeer, The Netherlands).
After macroscopic evaluation and photography of the wound, the size 
of the defect was measured between the marking sutures and was used 
to calculate wound contraction. Wound contraction was expressed as the 
percentage of the size of the defect at time of evaluation against the original 
size of the defect of 12 mm at time of surgery. All data are represented as 
mean ± SEM. The data were analyzed using computer statistical software 
(GraphPad Prism, GraphPad Software Inc.). The statistic significance of 
differences in the findings was evaluated by a one-way ANOVA followed 
by post hoc Bonferroni analysis. A difference was considered statistically 
significant when P < 0.05.
Histological techniques
Samples of the skin and subcutaneous tissue were taken at the level of the 
skin lesions, fixed in 4% (v/v) buffered formaldehyde and paraffin-embedded 
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for histological analysis or snap-frozen and stored at -80°C. Serial cross 
sections were cut (4 µm) and stained with haematoxylin and eosin, 
toluidine blue and Masson’s trichrome. Additionally, immunohistochemi-
cal stainings for α-smooth muscle actin (α-SMA), pancytokeratin and type 
IV collagen were performed on paraffin embedded sections. The sections 
were deparaffinized and washed with PBS. Endogenous peroxidases were 
blocked with 3% (v/v) H2O2/PBS for 30 min at room temperature. Heat 
mediated antigen retrieval in Sodium Citrate Buffer (10 mM Sodium 
Citrate, pH 6.0) during 10 minutes was performed for sections stained for 
α-SMA and cytokeratin. Sections stained with anti-type IV collagen were 
treated with 0.1% (v/v) protease (Sigma-Aldrich, St. Louis, MO, USA) for 
30 min at room temperature for antigen retrieval. Slides were pre-incubated 
with 5% serum from the species that produced the secondary antibody.
α-SMA was detected with mouse α-SMA (1:15.000, clone 1A4; 
Sigma-Aldrich) and peroxidase-conjugated goat-anti-mouse antibody 
(1:200; SBA, Birmingham, USA, cat.no.1080-05). Immunostaining 
of cytokeratin was performed by overnight incubation at 4°C of mouse 
anti-cytokeratin (1:800, clone AE1/AE3; Labvision corporation, Fremont, 
USA), followed by biotinylated horse-anti-mouse and peroxidase 
conjugated ABC complex (Vector Laboratories, Burlingame, USA). Type 
IV collagen was detected using rabbit anti-type IV collagen (1:100; Abcam, 
Cambridge, UK), biotinylated goat-anti-rabbit (Dako) and peroxidase 
conjugated streptavidine (Dako). Color development was performed 
with power DAB (α-SMA and cytokeratin, Immunologic, Duiven, The 
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Steinheim, Germany). Sections were counterstained with Mayer’s 
haematoxylin (Fluka Chemie, Buchs, Switzerland).
Results
Scaffolds
Scanning electron microscopy revealed a porous scaffold with a rather 
open top side and a more closed pan side (Fig. 1A). Crosslinking efficiency 
was 31 ± 8% for COL scaffolds and 31 ± 4% for heparinised COL scaffolds 
(mean ± SD). To heparinised COL scaffolds, 13.1 ± 2.4% heparin was 
bound (mean ± SD). Heparin was bound evenly throughout the scaffold. 
Figure 1.  Scanning electron microscopical images of collagen scaffolds crosslinked in the absence 
(top row) or presence of heparin (bottom row) (A). Shown are the top view, bottom view and cross-
section. The more closed pan side was implanted such that it was in contact with the amniotic fluid. 
Immunolocalisation of heparin, VEGF and FGF2 in the COL-HEP/VF scaffolds (B). Note that 
heparin and FGF2 were evenly distributed through the scaffold, while VEGF was mainly found at 
the edge of the scaffold.
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The amount of growth factors bound per mg heparinised COL scaffold 
was 0.26 ± 0.05 µg for VEGF and 0.10 ± 0.04 µg (mean ± SD) for FGF2. 
FGF2 was present throughout the scaffold whereas VEGF was mainly 
present at the edges of the scaffold (Fig. 1B).
Animal surgery
Eight ewes and 13 fetal lambs underwent surgery (6 ewes were bearing 
twins). The overall fetal survival rate was 85% during the pregnancy 
period. In one sheep, twin pregnancy could not be determined at time 
of surgery and only one fetus was operated. One sheep aborted 2 days 
after the surgery probably due to severe enteritis of the ewe and needed 
to be sacrificed accounting for the only maternal death in the study. At 
autopsy, herniation of a bowel loop between the fascial sutures was found. 
In one sheep, a thermal intestinal lesion occurred during the surgery which 
was repaired. All other procedures went uneventful. Eleven lambs were 
evaluated; four in group 1 (93 days), three in group 2 (107 days) and four 
in group 3 (140 days). The survival rate was similar to previously published 
data for fetal surgery on similarly aged fetal lambs [5-7].
Macroscopic evaluation
A macroscopic overview with examples of wound healing is depicted 
in Fig. 2A. On macroscopic inspection, the skin defects were visible in 
all groups. The untreated defects were completely closed at 8 weeks post 
surgery, with the wound edges contracted to each other. COL treated 
wounds showed remnants of the scaffold at 2 and 4 weeks post surgery, 
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Figure 2. Macroscopical overview of wound healing after surgery at 93 days’ (2 weeks post surgery), 
107 days’ (4 weeks post surgery) and 140 days’ gestation (term) (A). Note the shape of contraction 
of the untreated lesion and the reddish appearance of the wound treated with COL-HEP/VF. 
Percentage of wound contraction (B). At 2 and 4 weeks post surgery less contraction was present 
in COL treated wounds compared to untreated wounds. At all time points less contraction was 
present in COL-HEP/VF treated wounds compared to untreated wounds. * significant difference 
between untreated and COL or COL-HEP/VF (p<0.05). # significant difference between COL 
and COL-HEP/VF treated (p<0.05). 
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visible remnants of the scaffold. A reddish appearance of the remnants 
of the COL-HEP/VF treated wounds was present at 2 weeks, suggesting 
angiogenesis. In contrast to COL treated wounds, COL-HEP/VF treated 
wounds showed remnants of the scaffold at term. 
The percentage of wound contraction of the treated and untreated defects 
is shown in Fig. 2B. At 2 weeks, the percentage of wound contraction of the 
COL treated defects was decreased and this was more obvious when using 
a COL-HEP/VF scaffold. At 4 and 8 weeks, contraction was also found 
in the COL treated defects but again the contraction of the COL-HEP/VF 
scaffold was less (~30%). At term, the degree of wound contraction of the 
uncovered group was almost 80%.
Microscopic evaluation
Two weeks after surgery (93 days’ gestation), the untreated wounds 
were covered by a fibrin clot. The newly formed epidermis fully closed 
the wound area and separated the granulation tissue from the clot; the 
epidermal cells had migrated over the interface between the clot and the 
developing granulation tissue. The newly formed epidermis was, at this 
time point, less than twice as thick as the normal epidermis distal from 
the wound area (Fig. 3A); the overall thickness was very regular (Fig. 
4A). The granulation tissue consisted of a more open extracellular matrix 
(ECM) network compared to the normal dermis and was populated by 
numerous cells (Fig. 3A2). The latter appeared to be mainly myofibroblasts 
as based on their morphology and confirmed by αSMA staining (Fig. 5A). 
Compared to the normal fetal dermis in development, less mature blood 
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Figure 3. Masson’s trichrome staining of skin defects at different time points. Untreated defect at 
2 weeks (A), 4 weeks (D) and 8 weeks (G). Defect treated with COL at 2 weeks (B), 4 weeks (E) 
and 8 weeks (H). Defect treated with COL-HEP/VF at 2 weeks (C), 4 weeks (F) and 8 weeks (I). 
The black striped line indicates the edge of the defect; the black dotted line indicates the border 
between surrounding tissue and the scaffold.  E = epidermis, D = dermis, S = scaffold. The boxed 
areas denote the corresponding region of higher magnification images. Original magnifications: 
50x (A–I) and 200x (A1-I1). 
44
Chapter 2
The wounds treated with the COL scaffold showed a fibrin clot covering 
the top of the scaffold (not shown). Interestingly, the epidermis grew from 
both sides through the upper part of the scaffold, but did not completely 
close at this time point.  The thickness and shape of the newly formed 
epidermis was rather irregular (Fig. 3B, 4B) and was generally thicker than 
the epidermis of the untreated wound (i.e. the wound without a scaffold). 
New ECM formation occurred at the interface between the scaffold and 
the epidermis (Fig. 3B1), whereas less ECM formation was observed at the 
dermal side of the scaffold (Fig. 3B2). Infiltration of cells, mainly αSMA 
positive (Fig. 5B), was seen in the scaffold. In the scaffold only a few small 
blood vessels were formed (Fig. 3B). 
The wounds treated with the COL-HEP/VF scaffold also showed a 
fibrinous clot on top of the scaffold. Here again, the epidermis grew from 
both sides through the upper part of the scaffold. However, the newly 
formed epidermis was much more hyperplastic (Fig. 3C versus 3B; Fig. 
4C versus 4B) with a highly irregular shape. The wound area was also not 
completely covered by the epidermis. Less ECM formation was seen at the 
interface between the scaffold and the epidermis compared to the wound 
treated with the bare COL implant (Fig. 3C1 versus 3B1; Fig. 3C2 versus 
3B2) and fewer αSMA-positive cells infiltrated into the scaffold (Fig. 5C 
versus 5B). A few small blood vessels were present in the scaffold (Fig. 3C), 
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Four weeks after surgery (107 days’ gestation), the clot of the untreated 
wounds was not longer present and the thickness of the newly formed 
epidermis was completely normalized (Fig. 3D and Fig. 4D). A more dense 
ECM network was formed. A general decrease in cell number was seen 
(Fig. 3D1 and 3D2 versus 3A2); myofibroblasts were only sporadically 
seen (Fig. 5D). At this time point more small as well as mature blood 
vessels were observed at the dermal side of the newly formed tissue (Fig. 
3D2) compared to two weeks, however less blood vessels than in the 
normal fetal dermis.
In the wounds treated with COL, the clot was still present (Fig. 3E). 
The thickness of the newly formed epidermal layer was not normalized 
(Fig. 4E), but the wound area was completely covered by the epidermis 
Figure 4. : Epithelialization. Cytokeratin staining of skin defects at different time points. Untreated 
defect at 2 weeks (A), 4 weeks (D) and 8 weeks (G). Defect treated with COL at 2 weeks (B), 4 
weeks (E) and 8 weeks (H). Defect treated with COL-HEP/VF at 2 weeks (C), 4 weeks (F) and 8 
weeks (I).  Original magnifications: 50x (A–I).
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at this time point. Single cells were present between the collagen bundles 
of the entire scaffold (Fig. 3E2) and numbers of αSMA-positive cells 
were even decreased compared to the earlier time point (Fig. 5E vs Fig. 
5B). Most importantly, a newly formed ECM layer was present between 
the epidermis (Fig. 3E and 3E1) and the scaffold which was devoid of 
myofibroblasts (Fig. 5E) and in which several blood vessels were formed, 
comparable to the appearance of the normal dermis. Only a few mature 
blood vessels were formed in the scaffold as revealed by a collagen IV 
staining (Fig. 6A).  
In the wounds treated with COL-HEP/VF the clot was also still present. 
The newly formed epidermis was still hypertrophic with an irregular shape 
(Fig. 4F). ECM formation was mostly observed at the epidermal side of 
Figure 5. Myofibroblasts. SMA staining of skin defects at different time points. Untreated defect 
at 2 weeks (A), 4 weeks (D) and 8 weeks (G). Defect treated with COL at 2 weeks (B), 4 weeks (E) 
and 8 weeks (H). Defect treated with COL-HEP/VF at 2 weeks (C), 4 weeks (F) and 8 weeks (I). 
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Figure 6. Vascularization. Collagen IV staining of skin defects at different time points.  Defect 
treated with COL at 4 weeks (A) and 8 weeks (C). Defect treated with COL-HEP/VF at 4 weeks 
(B) and 8 weeks (D).  The boxed areas denote the corresponding region of higher magnification 
images. Original magnifications: 50x (A–E)  and 200x (A1-E1).
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the scaffold (Fig. 3F1) and contained a decreased amount of myofibroblasts 
(Fig. 5F) compared to the earlier time point. In the scaffold further distal of 
the epidermis hardly any ECM formation was seen (Fig. 3F2). Compared 
to the bare COL implant, less cells, mainly αSMA-negative (Fig. 5F), were 
present in the scaffold (Fig. 3F2 versus 3E2), but a similar amount of 
blood vessels was present in the scaffold (Fig. 6B versus Fig. 6A). 
Eight weeks after surgery (140 days’ gestation), the untreated wound 
had completely lost its clot. The granulation tissue was entirely replaced 
by ECM and had a density comparable with the normal dermis (Fig. 3G). 
There were no skin appendages in the newly formed tissue (Fig. 4G) and 
myofibroblasts were absent (Fig. 5G). A comparable amount of mature 
blood vessels was present in this newly formed ECM (Fig. 3G) when 
compared to the normal fetal dermis. 
In the wounds treated with COL, the clot was also lost, whereas still 
parts of the epidermis were thickened (Fig. 3H). Interestingly, the entire 
scaffold was degraded and replaced by ECM (Fig. 3H). A decreased amount 
of myofibroblasts was seen compared to four weeks (Fig. 5E versus 5H).  A 
higher amount of blood vessels was present throughout the newly formed 
ECM layer (Fig. 3H1, 3H2 and 6C) compared to the normal dermis.
In contrast, in the wounds treated with COL-HEP/VF part of the clot 
was still present. The thickness of the epidermal layer had decreased (Fig. 
3I and 4I), but was still thicker than the newly formed epidermis of the 
untreated and the COL treated wound. Remarkably, some of the skin 
appendages of the epidermis were formed in the newly formed ECM (Fig. 
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in the untreated and the COL treated wound. In contrast to the latter, a 
considerable part of the scaffold was still present (Fig. 3I). Although it still 
concerned low numbers, a higher influx of cells was seen in the scaffold 
at this time point compared to four weeks after treatment (Fig. 3I2 versus 
3F2). The amount of myofibroblasts was decreased compared to the four 
week time point (Fig. 5I versus 5F). Besides mature blood vessels, many 
capillaries were formed in the scaffold (Fig. 6D and D1).  
Discussion
Fetal tissue engineering has been proposed as a new concept in the 
surgical reconstruction of birth defects in the fetal period [25]. However, 
despite being a promising concept, hardly any studies have been published 
to tackle the various steps needed to establish a proof-of-concept. In this 
study we investigated whether biodegradable scaffolds with or without 
growth factors can be used to treat full-thickness fetal skin defects which 
facilitate epidermal overgrowth and dermal repair. We studied the healing 
of these skin defects by use of a bare collagen type I (COL) scaffold, a 
heparinised COL scaffold loaded with VEGF and FGF2 (COL-HEP/VF), 
or left untreated (no scaffold). We hypothesized that the pro-angiogenic 
growth factors VEGF and FGF2 might enhance vascularization and 
epithelialization, leading to improved wound healing.
The study showed that at term (8 weeks post surgery) proper epidermal 
layers were formed in all defects. Less wound contraction occurred in 
COL treated defects compared to untreated defects. Even less contraction 
was present in defects treated with COL-HEP/VF, but in contrast to 
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COL treated defects, degradation of the scaffold was not completed at 
term. Concerning degradation of the scaffold, hardly or no macrophages 
infiltrated the COL and COL-HEP/VF scaffolds, suggesting that these cells 
did not play a role in fetal tissue engineering. Similar amounts or even less 
blood vessels were formed in the defects compared to the developing fetal 
dermis, with exception of COL-HEP/VF treated defects at term, showing 
excessive formation of capillaries in the scaffold. Overall, myofibroblasts 
were involved in the remodeling of the tissue, i.e. ECM formation and 
wound contraction. 
It is highly important that wound contraction and scar formation will 
be minimized after fetal skin defects, as the fetus grows rapidly. Therefore 
we investigated the formation of ECM and the amount of contraction in 
time. Previously, a fetal sheep model has shown that the transition period 
from scarless to healing with scar formation in sheep occurs between 
100-120 days [3]. However, fetal skin repair is not only dependant on 
gestational age, but also on the size of the defect. Wounds in mid-gestation 
fetal lambs of 2-4 mm heal without scarring, whereas wounds of 6-10 mm 
heal with formation of a scar [3]. In our study, wounds of 12 mm were 
made at 79 days of gestation. It was expected that the untreated wounds 
would heal with scar formation due to the size of the wound. Indeed, all 
untreated defects showed healing with scar formation and contraction. 
However, clearly less wound contraction was observed with COL 
treatment. Myofibroblasts have contractile characteristics in an attempt to 
close the wound. Another function of myofibroblasts is the production of 
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at two weeks postsurgery in untreated and COL treated wounds. At 4 and 
8 weeks myofibroblasts were still present in COL treated wounds, resulting 
in a larger area of newly deposited ECM. As hypothesized, treatment of 
the skin defect with COL-HEP/VF diminished contraction even more. In 
accordance with this, fewer myofibroblasts were present. This is probably 
due to the incorporation of FGF2, because in vitro and in vivo studies have 
shown that FGF2 can inhibit and reverse the differentiation of fibroblasts 
to myofibroblasts [13;14;26;27]. 
Implantation of a biomaterial, like our degradable type I collagen 
scaffold, will induce an inflammatory response by the non-specific 
immune system, known as the foreign body reaction (FBR). In general 
the FBR will induce resorption of degradable scaffolds after implantation. 
Key players in the adult FBR are macrophages and giant cells. However, 
little is known about the FBR in fetal applications. It is known that in fetal 
wound healing less inflammation is induced compared to adult wound 
healing, which can be due to the fact that the innate immune system is 
less mature in the fetus. In the current fetal lamb model hardly any or 
no macrophages were detected in any of the histological specimens, and 
most of the cells were myofibroblasts. We wanted to confirm the scarcity 
of macrophages by a macrophage staining, but antibodies against sheep 
macrophages are not available. Several other macrophage antibodies have 
been tested to see if these cross-react, but none of these antibodies were 
successful.  In accordance with the absence of macrophages, also giant cells 
(fused macrophages) were not present in the fetal skin wounds. This is a 
major difference with the adult situation in which implanted biodegradable 
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scaffolds are finally phagocytosed by giant cells. In the current fetal model, 
COL and COL-HEP/VF scaffolds did degrade but as mentioned giant 
cells were not involved, suggesting that the scaffolds were degraded by 
enzymes secreted by (myo)fibroblasts. 
In fetal tissue engineering it is important that a good balance exists 
between the degradation of the scaffold and new tissue formation, i.e. 
epithelial overgrowth and proper dermal regeneration. We observed 
a faster tissue remodeling in the COL treated wounds compared to 
COL-HEP/VF treated defects. At four weeks in COL treated wounds, 
part of the collagen scaffold was degraded and replaced by an ECM layer 
that integrated with the original dermis. At eight weeks, the entire scaffold 
was degraded and replaced by new ECM. In contrast, in the COL-HEP/
VF treated wounds, a large part of the scaffold was still present at 8 weeks 
post surgery, demonstrating that remodeling is still in progress. These 
differences between COL and COL-HEP/VF implicate that fetal TE can 
be influenced by growth factors leading to different degradation patterns.
Another major difference between COL and COL-HEP-VF treated 
defects was the hyperplasia of the epidermis observed at 2 and 4 weeks 
post surgery in COL-HEP/VF treated wounds. This could be caused by 
FGF2 as well as VEGF. It is known that FGF2 can have a mitogenic effect 
on keratinocytes, thereby promoting epithelialization in adult wound 
healing [15;16]. VEGF can also stimulate the proliferation and migration of 
keratinocytes in vitro [28]. Furthermore, application of VEGF in a diabetic 
wound healing model showed accelerated wound healing with enhanced 
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has been formed. Furthermore, enhanced angiogenesis was observed in 
the COL-HEP/VF treated wounds. Both VEGF and FGF2 can promote 
angiogenesis and the combination of VEGF and FGF2 has been shown 
to have synergistic effects on neovascularization both in vitro and in vivo 
[9-12]. Although excessive formation of capillaries was observed in these 
scaffolds 8 weeks post surgery, we do not know whether these capillaries 
are functional, because erythrocytes were not observed in these capillaries. 
A highly interesting observation is the formation of new appendages 
in the wounded area of the COL-HEP-VF treated wounds 8 weeks 
after surgery. Regeneration of these specialized structures indicates an 
enhanced functional healing. These newly formed appendages were less 
mature (smaller compared to appendages in the normal skin at this time 
of development) than the appendages in the unwounded skin, indicating 
that the appendages have not migrated from the wound edges. 
For optimal binding of growth factors to the scaffold, the scaffolds were 
heparinised. We have to realize that directly after implantation the scaffold 
is in contact with the amniotic fluid. It is known that several growth 
factors are present in the amniotic fluid, like hepatocyte growth factor 
(HGF), insulin-like growth factor (IGF), FGF2, and VEGF. We can not 
exclude that, in addition to the loaded growth factors, also growth factors 
from the wound site or from the amniotic fluid bound to the heparin in 
COL-HEP-VF, leading to a long-term effect of these growth factors.
For future tissue engineering approaches of congenital defects such as 
spina bifida, scaffolds could be useful for wound closure. In utero coverage 
of the defect with a scaffold will shorten the exposure time of the spinal 
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cord to the amniotic fluid, which will likely improve the neurologic 
outcome by preventing further damage. However, future studies will be 
needed to investigate if the addition of growth factors is beneficial in the 
case of spina bifida. 
Conclusion
The evaluation of biomaterials for specific applications should be 
evaluated in model systems resembling the clinical situation. This study 
showed that tissue engineering in utero is a promising method in treatment 
of full thickness fetal skin defects. Both COL and COL-HEP/VF treated 
wounds showed a proper re-epithelialization and healing without a 
(chronic) FBR. COL treated wounds show less contraction than untreated 
wounds and this effect was even enhanced in COL-HEP-VF. Furthermore, 
the addition of these growth factors leads to an increased angiogenesis and 
to regeneration of the skin appendages. 
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Purpose Human amniotic fluid comprises cells with high differentiation 
capacity, thus representing a potential cell source for skin tissue engineering. 
In this experimental study we investigated the ability of human amniotic 
fluid derived cells to substitute dermal fibroblasts and support epidermis 
formation and stratification in a humanized animal model.
 
Methods Dermo-epidermal skin grafts with either amniocytes or with 
fibroblasts in the dermis were compared in a rat model. Full-thickness 
skin wounds on the back of immuno-incompetent rats were covered 
with skin grafts with (a) amniocytes in the dermis, (b) fibroblasts in the 
dermis, or, (c) acellular dermis. Grafts were excised 7 and 21 days post 
transplantation. Histology and immunofluorescence were performed 
to investigate epidermis formation, stratification, and expression of 
established skin markers.
 
Results The epidermis of skin grafts engineered with amniocytes showed 
near-normal anatomy, a continuous basal lamina, and a stratum corneum. 
Expression patterns for keratin 15, keratin 16, and Ki67 were similar to 
grafts with fibroblasts; keratin 1 expression was not yet fully established in 
all suprabasal cell layers, expression of keratin 19 was increased and not 
only restricted to the basal cell layer as seen in grafts with fibroblasts. In 
grafts with acellular dermis, keratinocytes did not survive.
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near-normal physiological behavior suggesting that amniocytes substitute 
fibroblast function to support the essential cross-talk between mesenchyme 
and epithelia needed for epidermal stratification. This novel finding has 





The composition of the amniotic fluid changes with gestational age. 
Whereas in the first half of gestation most of the fluid comes from active 
sodium and chloride transport across the amniotic membrane and the fetal 
skin, most of the fluid in the second half of gestation results from fetal 
micturition and lung water production [1]. The cells found in this fluid 
stem from all three germ layers and stem from the fetal skin, the digestive 
tract, and from the amniotic membranes [2]. Among the heterogeneous 
population of fetal cells that can be found in the amniotic fluid are 
mesenchymal, hematopoietic, epithelial, and trophoblastic cells [3].
Previous studies showed that the mesenchymal cells from the amniotic 
fluid (in this study referred to as amniocytes) express a phenotypic profile 
that is consistent with the profile of fetal mesenchymal progenitor cells, 
i.e. they are negative for CD31 and positive for vimentin, α-smooth 
muscle actin, keratin 8 and 18, and fibroblast surface protein [4, 5]. They 
express several, but not all, important markers for embryonic stem cells, 
i.e. they are positive for Oct-4, Nanog, and SSEA-4, indicating that they 
represent a new class of stem cells, situated between embryonic stem cells 
and adult stem cells [3, 6]. It was shown that amniocytes have an expansion 
capacity four to eightfold higher than bone marrow derived mesenchymal 
stem cells, and that they differentiate into various mesenchymal lineages, 
including fibroblasts, osteocytes, and adipocytes [7]. In culture, these cells 
secrete various cytokines and chemokines important in wound healing, 
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cells was successful over a period of 8 months with stable karyotype [9]. In 
addition, it was shown that amniocytes retain their proliferative capacity 
and differentiation potential also during decades of cryopreservation [10].
Autologous fetal tissue engineering was performed in different animal 
models for various postnatal surgical interventions such as bladder 
augmentation, diaphragmatic replacement, tracheal augmentation, 
and skin defects [11-14]. Of note, in these models, tissue engineering was 
performed using a biopsy of the respective organ and the engineered tissue 
was delivered only after birth.
For fetal tissue engineering purposes, the amniotic fluid is a very 
attractive cell source. Cells can easily be harvested from amniotic fluid 
aspirated during the frequently performed diagnostic amniocenteses [5]. 
The goal of this paper was to test whether amniocytes could be used for 
tissue engineering of skin. In particular, we wanted to investigate whether 
these amniocytes finally can assume anatomically and functionally the role 
of dermal fibroblasts.
Materials and Methods
Cell harvest and culture
Human skin samples were obtained after informed consent of the 
patients or parents; all described studies were approved by the Medical 
Ethical Committee of the Kanton Zurich. Human primary fibroblasts 
and keratinocytes were isolated and cultured according to the standard 
protocol, as previously described [15]. 
Confluent back-up human amniocentesis cultures were received after 
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informed consent of the patients from the clinical cytogenetics laboratory 
of the University Medical Center Groningen. Cells were cultured from 
healthy fetuses (with a normal karyotype). Cells were harvested and 
expanded in DMEM (Lonza, Breda, The Netherlands) supplemented with 
20% fetal calf serum (FCS; Perbio Science, Ettenleur, The Netherlands) 
and 1% penicillin, 1% streptomycin (10.000U/ml, Gibco, Paisley, UK) 
and 2 mM l-glutamine (Lonza, Breda, The Netherlands).
Engineering of dermo-epidermal skin substitutes
Skin grafts with either normal human dermal fibroblasts or human 
amniocytes in the dermis were prepared, using a previously established 
transwell system (6-well cell culture inserts with membranes of 3 µm 
pore-size (BD Falcon, Basel, Switzerland)) [15-17]. As negative control, skin 
substitutes with an acellular dermis were produced.
Briefly, bovine collagen type I (BD Biosciences, Basel, Switzerland) was 
mixed with either 1x105 human primary dermal fibroblasts or with 1x105 
human amniocytes, or, for the negative control, no cells, and neutralized 
with a buffer containing NaOH [18]. The solution was poured into the 
cell culture inserts. The hydrogels were plastically compressed [19] and 
cultivated in DMEM with 10% FCS. After 5 days, 7.5x105 keratinocytes 
were seeded onto the complete surface of all of the hydrogels. The grafts 
were cultivated for three days under submersed conditions in Rheinwald 
and Green keratinocyte medium, followed by three days cultivation at the 
air-liquid interface before transplantation onto immuno-incompetent rats. 
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Bright light microscopy
To compare the morphology of amniocytes and fibroblasts, bright 
light microscopic pictures were taken using a Nikon SMZ1500 stereo 
microscope with a Nikon DXM1200F camera.
Fluorescein diacetate live cell staining
The viability and morphological shape of the cells incorporated into 
the collagen type I hydrogels was compared using fluorescein diacetate 
(FdA) live cell staining [20]. Cell culture medium was removed and the 
hydrogels were incubated with 5 µM FdA (Sigma, Buchs, Switzerland) in 
PBS (Invitrogen, Basel, Switzerland). After two minutes, the FdA solution 
was removed and the hydrogels were washed with PBS. Fluorescein 
fluorescence was observed using a Nikon SMZ1500 fluorescent stereo 
microscope (FITC filter, Nikon DXM1200F camera).
Transplantation of dermo-epidermal skin grafts
Animal experiments were approved by the local Committee for 
Experimental Animal Research. Immuno-incompetent nu/nu rats (age 
8-10 weeks, Harlan, Horst, The Netherlands) were prepared as previously 
described [16, 17, 21, 22]. To prevent wound closure by the surrounding skin, 
steel rings (diameter 26 mm) were implanted into full-thickness skin 
defects on the back of the rats and served as a modified Fusenig chamber 
[23]. The transplants were inserted into the ring and covered with a silicon 
foil (Silon-SES, BMS, Allentown, PA, USA). Animal numbers were: 
amniocyte-grafts excised 7 days post transplantation n=6; amniocyte-grafts 
excised 21 days post transplantation n=6; fibroblast-grafts excised 7 days post 
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transplantation n=6; fibroblast-grafts excised 21 days post transplantation 
n=6; grafts with acellular dermal part excised 21 days post transplantation 
n=6. Wound dressing changes and photographic documentations (Nikon 
D90) were performed every 7 days. Animals were sacrificed 7 or 21 days 
post transplantation. Transplants were excised, halved, and embedded in 
O.C.T compound (Tissue-Tek®, Sakura Finetek, Japan), or fixed in 4% 
paraformaldehyde (Medite Medizintechnik AG, Nunningen, Switzerland) 
and embedded in paraffin (McCormick, Richmond, USA).
Histology and immunofluorescence
Paraffin sections (sectioned at 10 µm with a microtome from Leica, 
Wetzlar, Germany) were deparaffinized and stained with hematoxylin & 
eosin (Sigma, Buchs, Switzerland) and imaged by light microscopy (Nikon 
Eclipse TE2000-U inverted microscope connected with a DXM1200F 
digital camera (Nikon AG, Egg, Switzerland).
O.C.T embedded tissue was frozen at -20 °C and sectioned at 10 µm 
(Leica, Wetzlar, Germany). Sections were permeabilized in ice-cold acetone 
for 5 minutes, air-dried, and washed three times with phosphate buffered 
saline (PBS, Invitrogen, Basel, Switzerland). Blocking was performed with 
PBS containing 2% bovine serum albumin (Sigma, Buchs, Switzerland) 
for 30 minutes at room temperature. Sections were incubated with 
the pre-labeled antibodies for 1 hour at room temperature. After three 
washing steps with PBS, nuclei were stained with 1 µg/ml Hoechst 33341 
(Sigma, Buchs, Switzerland) in PBS for 5 minutes at room temperature. 
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fluorescent mounting solution (Dako, Baar, Switzerland).
Antibodies
The following antibodies were used: K1 (clone LHK1, 1:200, 
Novus Biologicals, Littleton, USA); K15 (clone SMP190, 1:50, Spring 
Biosciences, Fermont, USA); K16 (clone LL025, 1:100, Chemicon 
International, Temecula, USA); K19 (clone RCK108, 1:100, Dako, 
Glostrup, Denmark); Ki67 (clone B56, 1:100, ABD Serotec, Dusseldorf, 
Germany); Lam5α3 (clone P3H9-2, 1:100, Santa Cruz, Labforce AG, 
Nunningen, Switzerland) [24].
For immunofluorescence stainings, primary antibodies were pre-labeled 
with either Alexa488 or Alexa555 conjugated polyclonal goat F(ab’)2 
fragments, according to the manufactor’s instructions (Zenon Mouse IgG 
Labelling Kit, Molecular Probes, Invitrogen, Basel, Switzerland).
Fluorescence microscopy
Immunofluorescence stainings were analyzed using a Nikon Eclipse 
TE2000-U inverted microscope, equipped with Hoechst, FITC and 
TRICT filter sets and connected with a DXM1200F digital camera (Nikon 
AG, Egg, Switzerland). Images were processed with Photoshop 7.0 (Adobe 
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Mesenchymal cells from human amniotic fluid (amniocytes) were 
isolated, cultured and passaged several times. Upon 90% - 100% confluence, 
the amniocytes (Fig. 1a) demonstrated a rather irregular arrangement as 
opposed to the one of human fibroblasts (Fig. 1b) that appeared to be more 
“streamlined”. The amniocytes shared the spindle-shaped morphology 
with fibroblasts.
Figure 1. Comparison of morphology of human primary amniocytes and human primary 
fibroblasts on cell culture plastic (2D) and in a collagen hydrogel (3D). a Phase contrast microscopy 
of amniocytes shows cell morphology similar to spindle-shape morphology of fibroblasts (b). 
c Positive fluorescein diacetate staining of amniocytes in collagen hydrogel shows dendrite 
morphology and good viability of the cells. d Fluorescein diacetate staining of fibroblasts indicating 




Healthy amniotic fluid cells 
Figure 2. Macroscopic views of grafts at time point of transplantation (day 0), 7 and 21 days post 
transplantation. a–c Transplants show similar appearance at the day of transplantation. d, e Seven 
days post transplantation, the surface of both amniocyte- and fibroblast-grafts is similar and looks 
rather dull and dry. f Grafts with acellular dermis appear more shiny and moist. g, h Twenty-one 
days post transplantation, grafts with amniocytes and with fibroblasts look similar as shown in d, e. 
i Twenty-one days post transplantation, grafts with acellular dermis look similar as described in f. 
Diameter of the ring (arrow in a) 26 mm (a–i)
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Amniocytes were incorporated into bovine collagen type I hydrogels 
and FdA staining was performed three days thereafter to assess the viability 
of the cells as well as their morphology in this 3D culture system. FdA 
staining revealed high cell viability with spindle-shaped, dendrite, or 
stellate morphology of the cells (Fig. 1c), similar to fibroblasts in collagen 
hydrogel (Fig. 1d).
Macroscopic appearance of epidermis development on transplanted grafts
At transplantation of the three types of skin substitutes (amniocytes 
in the dermis, fibroblasts in the dermis, or, acellular dermis) on the back 
of immuno-incompetent rats, no macroscopic difference between the 
three types of transplants could be observed (Fig. 2a-c). Seven days post 
transplantation, complete take of all grafts in all animals was observed 
(Fig. 2d-f ). The presence or absence of an epidermis was difficult to asses 
macroscopically at this early stage, although the transplants with acellular 
dermis appeared to have a rather moist surface (Fig. 2f ), usually indicating 
a missing or poorly developed epidermis. 21 days post transplantation, 
grafts containing amniocytes or fibroblasts showed a clearly epithelialized 
surface and seemed well integrated into the rat tissue (Fig. 2g-h). Grafts 
with an acellular dermis had a moist surface (Fig. 2i) and appeared smaller 
compared to the other transplants.
Histological analysis of the epidermis
Excised grafts were sectioned and stained with hematoxylin & eosin. 
Seven days post transplantation, skin substitutes with amniocytes (Fig. 3a) 




Healthy amniotic fluid cells 
Figure 3. Histological evaluation of the excised grafts (hematoxylin & eosin staining). a Seven days 
post transplantation, amniocyte-grafts show a correctly stratified epidermis with 4–6 cell layers 
and a stratum corneum. The collagen gel is easily discernable. b Seven days post transplantation, 
fibroblast-grafts look similar as described in a. The collagen gel is similar as in a. c Twenty-one days 
post transplantation, the epidermis of amniocyte-grafts is near physiological and has 6–8 cell layers. 
The dermis is markedly populated by cells. d Twentyone days post transplantation, the epidermis 
of fibroblast-grafts is up to 8–10 cell layers thick including stratum corneum, and the dermis is 
densely populated by cells. e Twenty-one days post transplantation, grafts with acellular dermis 
show neither epidermis nor single epidermal cells. The collagen gel is easily detectable and a large 
part of it does not contain cells. The dotted line indicates the border between graft and underlying 
tissue. Arrows point at stratum corneum. cg; Collagen gel. Scale bars 100 µm (a–e).
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Figure 4. Immunofluorescence stainings of grafts with amniocytes or with fibroblasts in the dermis 
21 days after transplantation. a, b Staining of the basement membrane component laminin 5 (red) 
reveals the deposition of a continuous basement membrane in both types of transplants. Expression 
of keratin 1 (green) is not fully  stablished in all suprabasal layers in amniocyte-grafts, whereas in 
fibroblast-grafts, all suprabasal layers express  keratin 1. c, d In both types of transplants, keratin 16 
(red) is expressed in all suprabasal layers. Proliferation as indicated by expression of Ki67 (green) 
in the basal cell layer of amniocyte-grafts is more pronounced compared to fibroblast-grafts. Prolif-
eration of cells in the dermal part is lower in amniocyte-grafts than in fibroblast-grafts. e, f In 
amniocyte-grafts, keratin 19 (red) expression is detected in most suprabasal cells, whereas in fibrob-
last-grafts keratin 19 expression is restricted to some basal cells. In both types of grafts, keratin 15 
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anatomy and a stratum corneum. The dermal part of these grafts was 
clearly distinguishable from the underlying tissue, and evenly distributed 
cells could be detected in the dermis (Fig. 3a). Similar features were 
observed in grafts with fibroblasts (Fig. 3b). 21 days post transplantation, 
the neodermis in transplants with amniocytes and with fibroblasts showed 
a higher cell number than 7 days post transplantation, and the epidermis 
demonstrated about 6-8 layers on the amniocyte-grafts (Fig. 3c) and about 
8-10 layers on the fibroblast-grafts (Fig. 3d). 21 days post transplantation, 
a large part of the dermis in grafts with acellular dermis was devoid of any 
cells, and no epidermal elements were detectable (Fig. 3e). 
Basal lamina deposition, epidermal homeostasis and proliferation
Grafts excised 21 days post transplantation were sectioned and 
immunofluorescence stainings were performed. Staining of the 
amniocyte-grafts with an antibody to the basal lamina component laminin 
5 (Fig. 4a) demonstrated a deposition of a continuous basal lamina in 
all transplants and keratin 1 expression was not fully established in all 
suprabasal layers (Fig. 4a). In fibroblast-grafts in the dermis, laminin 5 
staining revealed a continuous basal lamina and keratin 1 was expressed 
in all suprabasal layers (Fig. 4b). In amniocyte-grafts, keratin 16 was 
continuously expressed in all suprabasal layers (Fig. 4c). Amniocyte-grafts 
demonstrated more cells expressing the proliferation marker Ki67 in 
the basal layer (Fig. 4c), while the fibroblast-grafts demonstrated more 
Ki67 positive cells in the dermis (Fig. 4d). In fibroblast-grafts, keratin 16 
expression was found in all suprabasal layers (Fig. 4d). In amniocytes-grafts, 
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keratin 15 expression could be observed in most of the basal cells, whereas 
expression of keratin 19 was detected in most suprabasal cells (Fig. 4e). In 
fibroblast-grafts, keratin 15 expression was found in most basal cells, and 
a subpopulation of these basal cells was positive for keratin 19 (Fig. 4f ).
Discussion
We describe here the generation of dermo-epidermal skin grafts 
containing human primary amniotic fluid derived cells in the dermis 
instead of human fibroblasts. These tissue engineered skin substitutes 
were compared to tissue engineered dermo-epidermal skin substitutes 
with human primary fibroblasts in the dermis and grafts with an acellular 
dermis. The key finding of our study is that the amniocytes can competently 
substitute for fibroblasts and successfully support epidermis stratification 
and survival. Some aspects deserve detailed consideration.
The interaction between epithelium and underlying mesenchyme was 
studied extensively for many years. It became clear that for successful 
epidermal stratification and survival, an underlying mesenchyme is 
absolutely mandatory. The mesenchyme provides essential growth 
factors to the epithelial cells and so stimulates the stratification of the 
epidermis [25-28].
It was therefore not surprising that we could not observe epidermis 
stratification, nor survival, in our skin grafts created with an acellular 
dermis. Interestingly, transplants with amniocytes in the dermis showed 
near normal structure, comparable to control transplants with fibroblasts 
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near normal epidermis including a stratum corneum and deposited 
a continuous basal lamina. However, expression patterns for markers 
of epidermal homeostasis suggested that 21 days post transplantation 
the epidermis was not yet in a fully homeostatic state. This aspect was 
reinforced by the detection of many suprabasal cells that were positive 
for keratin 19 expression, compared to the fibroblast-grafts where keratin 
19 expression was restricted to some basal cells. These findings indicate 
that the development of the epidermis within amniocyte containing grafts 
is basically physiological, but slightly slower than in those containing 
fibroblast. These results provide compelling evidence that amniocytes 
incorporated into the dermal part of a dermo-epidermal skin graft can 
efficiently substitute fibroblasts and correctly support epidermal survival 
and stratification.
Diagnostic amniocentesis is routinely offered, can be safely performed 
under ultrasound guidance, and is associated with a very low rate of 
spontaneous abortion of only 0.5% [29]. The removal of an additional small 
aliquot of amniotic fluid does not represent an additional risk to fetus or 
mother and also does not apparently constitute an ethical concern.
The present study can be seen as a first step towards tissue engineering 
of fetal skin without the necessity of harvesting a formal fetal skin biopsy. 
We demonstrate that prenatally harvested amniocytes can be successfully 
employed to competently assume the role of dermal fibroblasts in a 
fetal-postnatal hybrid skin substitute (amniocytes = fetal cells, keratinocytes 
= postnatal cells). Of note, amniotic fluid also contains fetal epidermal 
cells that, hypothetically, might also be harvested, isolated, cultured, so as 
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to form a fetal epidermis. Taken together, in a best case future scenario, 
autologous “fetal skingineering” could be accomplished by the sole use of 
amniotic fluid.
What are then, theoretically, possible applications for such laboratory 
grown fetal skin? Human fetal surgery for spina bifida is a reality today 
and represents a novel standard of care for select fetuses suffering from 
that devastating malformation [30] (also at our center [31]).  Quite often, 
the back lesions of these fetal patients are too big for successful primary 
skin closure. In those situations an “off-the-shelf ” autologous fetal skin 
substitute might represent an ideal way to guarantee adequate skin coverage. 
Another hypothetical application might be the use of amniotic fluid 
derived bioengineered fetal skin to treat chronic skin wounds, particularly 
in polymorbid elderly patients which often demonstrate notorious wound 
healing problems. It is in fact conceivable that fetal skin (even if allogenic) 
harbors more wound healing power [8] than postnatal skin substitutes used 
for the same purpose [32, 33]. Finally, one could even think of harvesting 
and cryopreserving amniotic fluid for any potential use later in life. It was 
in fact shown that stored amniocytes remain viable and functional over 
decades of cryopreservation [10]. If the same holds true for amniotic fluid 
derived epidermal cells, then autologous skin might be engineered at any 
age of the patient for a number of possible indications (giant nevi, burns, 
scar revisions, chronic wounds, and other conditions where larger areas of 
skin are lost).
In summary and conclusion, we demonstrate here that amniocytes 
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of bioengineering a full-thickness skin analog. This novel finding has 
fundamental implications on the emerging field of tissue engineering and 
harbors considerable potential regarding in vitro fabrication of both fetal 
and adult skin.
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In spina bifida the neural tube fails to close during the embryonic 
period. Exposure of the neural tube to the amniotic fluid during pregnancy 
causes additional neural damage. Intra-uterine tissue engineering, using a 
biomaterial seeded with stem cells, might prevent this additional damage. 
For this purpose, autologous cells from the amniotic fluid are an attractive 
source. In order to close the defect it is important that these cells deposit 
extracellular matrix. However, it is not known if amniotic fluid cells 
from a fetus with a neural tube defect share the same characteristics as 
amniotic fluid cells from a healthy fetus. We found that cells derived from 
fetuses with a neural tube defect, in contrast to healthy human amniotic 
fluid cells, did not deposit collagen type I. Furthermore, the neural tube 
defect cells showed, compared to both healthy amniotic fluid cells and 
fetal fibroblasts, a much  lower mRNA expression levels of genes that are 
involved in collagen biosynthesis (PCOLCE, PCOLCE2, ADAMTS2, 
ADAMTS14). This indicates that neural tube defect amniotic cells have 
different characteristics as healthy amniotic fluid cells and might not be 
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Introduction
In open spina bifida (myelomeningocele) there is an incomplete 
closure of the neural tube at the end of the first month of embryonic 
development. Neural tube defects (NTD), one of the most common 
congenital malformations, are associated with severe lifelong disabilities, 
including mental impairment, paraplegia, urinary and fecal incontinence 
and skeletal deformities . Treatment of NTD consist of closing the 
spinal lesion after birth (postnatal surgery), thereby preventing infection. 
However, if detected during pregnancy, fetal surgery can be performed in 
order to close the defect [1-4]. It has been found that closure of the defect 
in utero results in an improved outcome [4]. This has been explained by 
the “two-hit hypothesis”: the failure of neural tube closure (first hit) is 
followed by additional damage to the neural tissue due to amniotic fluid 
exposure (second hit). Repair in utero attenuates this secondary damage [1]. 
The therapeutic potential of tissue engineering for prenatal NTD coverage 
has been shown with collagen/gelatin scaffolds in preclinical models [5-11]. 
So far, scaffolds loaded with cells have not been used. 
Amniotic fluid contains a population of mesenchymal progenitor cells 
that can be used as a cell source for fetal surgical therapy. This concept has 
been introduced about a decade ago by the group of Fauza [12-19]. In short, 
some congenital anomalies detected by prenatal imaging can, in principle, 
be surgically treated in utero with autologous amniotic fluid stem cells 
(AFCs). These cells can be isolated and expanded from amniotic fluid 
obtained from amniocentesis. By seeding these cells in a scaffold, a fetus 
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can benefit from such an autologous graft in surgical procedures aimed at 
repairing the congenital anomaly (fetal tissue engineering) [20-23]. Several 
reports describe the differentiation of the multipotent AFCs into cell types 
such as adipocytes, chondrocytes, osteoblasts, or smooth muscle cells [24-31]. 
Cartilage and tendon grafts derived from AFCs have successfully been used 
in fetal repair efforts in large animal models [14;18;19]. In a previous study, we 
showed that AFCs from healthy fetuses can be used to repair skin defect[32]. 
Since the NTD coverage must be complete, in order to prevent leakage 
of amniotic fluid to the underlying tissues, we questioned whether AFCs 
can be used to accelerate the repair in utero. For future therapy, autologous 
AFCs are preferred, to reduce the chance of rejection. However, no studies 
have been performed with AFCs derived from fetuses with a NTD, therefore 
it is not known whether these cells can be used for tissue engineering. 
In tissue engineering, mesenchymal progenitor cells need to be 
differentiated into specialized cells in order to produce the required 
connective tissue (e.g. chondrocytes to produce cartilage, or osteoblasts 
to produce bone). However, mesenchymal progenitor cells have many 
fibroblast-like properties [33-36]. We hypothesized that a “one-step” 
procedure might be possible, namely that NTD-AFCs can be placed in 
the biomaterial without performing a differentiation step, and that these 
AFCs subsequently produce a covering connective tissue rich in collagen 
type I.
As a first step to test this hypothesis, we have investigated the response 
of NTD-AFCs on transforming growth factor β1 (TGF-β1), a cytokine 
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of healthy AFCs and fetal human dermal fibroblasts. Remarkably, collagen 
type I production was observed in fetal dermal fibroblasts and healthy AFCs 
after TGF-β1 stimulation, but not in NTD-AFCs. Since the biosynthesis 
of collagen is a complex process involving a number of post-translational 
modifications, we subsequently characterized the expression pattern of 
genes involved in collagen biosynthesis of NTD-AFCs and healthy AFCs 
and compared this with fetal human dermal fibroblasts. We found that 
healthy AFCs closely resemble fetal dermal  fibroblasts in terms of collagen 
homeostasis, but that NTD-AFCs show a strikingly different expression 
pattern which might explain the impaired collagen deposition.
Materials and methods
Cell culture
Confluent “back-up” human amniocentesis cultures were received 
from the clinical cytogenetics laboratory of the University Medical Center 
Groningen. Cells were cultured from healthy fetuses (H-AFCs, n=4, 
with a normal karyotype) and cells derived from fetuses diagnosed with 
a neural tube defect (NTD-AFCs, n=4, with a normal karyotype). Cells 
were harvested and expanded in DMEM (Lonza, Breda, the Netherlands) 
supplemented with 20% fetal calf serum (FCS; Perbio Science, Etten-Leur, 
the Netherlands) and 1% penicillin, 1% streptomycin (10.000  U/ml, 
Gibco, Paisley, UK) and 2 mM L-glutamine (Lonza). After passage 4, cells 
were cultured in DMEM supplemented with 10% FCS, 1% penicillin, 
1% streptomycin and 2 mM L-glutamine. 
Primary fetal human dermal fibroblasts (HDF-f; Sciencell (#2300), 
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Carlsbad, USA and Cell Applications (106-05f ), San Diego, USA)  were 
cultured in DMEM supplemented with 10% FCS, 1% penicillin, 1% 
streptomycin and 2 mM L-glutamine. 
Fluorescence-activated cell sorting
AFCs (from passage 5-7) were incubated with FITC-conjugated CD34 
antibodies (1:10; IQ products (IQP-114F), Groningen, the Netherlands), 
FITC-conjugated CD44 antibodies (1:10; IQ products (IQP-118F)), 
FITC-conjugated SSEA4 antibodies (1:10; Abcam (ab16287), Cambridge, 
UK), PE-conjugated CD45 antibodies (1:10; IQ products(IQP-124R)) 
and PE-conjugated CD90 antibodies (1:10; R&D systems (FAB2067P), 
Abingdon, UK) at 4°C for 30 minutes, followed by a wash step in PBS 
containing 0.2% bovine serum albumin (BSA; Sanquin, Amsterdam, the 
Netherlands). For Oct4 staining, cells were first fixed with 2% paraformalde-
hyde (Merck, Darmstadt, Germany) for 10 minutes, permeabilised and 
incubated with an unconjugated Oct4 antibody (1:100; Abcam (ab19857), 
Cambridge, UK) for 30 minutes at 4°C. Cells were washed and incubated 
for 15 minutes with swine anti-rabbit TRITC (1:20; Dako, Glosstrup, 
Denmark), followed by a wash step in PBS containing 0.2% BSA. Cells 
were analysed using a FACS Caliber system (BD Biosciences, San Jose, 
USA). Data were analyzed by FlowJo software (Tree Star, Ashland, USA). 
Collagen I deposition by HDF-f, H-AFCs and NTD-AFCs after TGF-β1 
stimulation
HDF-f (ATCC (CCL-110), Manassas, USA), H-AFCs and NTD-AFCs 
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(Nunc, New York, USA) in DMEM with 10% FCS. After 24 hours the 
medium was removed and replaced with medium containing 0.5% FCS 
and 50 ng/ml L-ascorbic acid 2-phosphate sesquimagnesium salt hydrate 
(Sigma-Aldrich, Zwijndrecht, the Netherlands) overnight. Subsequently, 
cells were exposed with or without 10 ng/ml recombinant human TGF-β1 
(Peprotech, Rocky Hill, USA) for 3 days, with daily medium replacements. 
After 3 days of culture (with or without TGF- β1), cells were washed 
twice with PBS and fixed in 2% paraformaldehyde at room temperature for 
10 minutes. Fixed cells were incubated with mouse anti-human collagen I 
(1:100; Abcam (ab90395)) diluted in PBS containing 1% BSA for 1 h at 
room temperature. After three washes with PBS, cells were incubated with 
biotinylated goat anti-mouse IgG1 (1:100; SouthernBiotech, Alabama, 
USA) diluted in PBS containing 1% BSA for 30 min at room temperature. 
Then the cells were washed three times with PBS and incubated with 
streptavidine-CY3 (1:400; Dako, Glosstrup, Denmark) in PBS containing 
1% BSA, 2% normal human serum and DAPI (1:5000) for 30 min. After 
three washes with PBS slides were mounted in Citifluor (Agar Scientific, 
Stansted, UK) and visualized using a Leica DMRA Immunofluorescence 
microscope and Leica software (Leica Microsystems, Wetzlar, Germany).
Gene expression analysis
HDF-f, H-AFCs and NTD-AFCs (for all cell types passage 5 or 6) 
were seeded at a density of 15.000/cm2 in 6 wells plates (Corning B.V. Life 
Sciences, Amsterdam, The Netherlands) in DMEM supplemented with 
10% FCS, 1% penicillin, 1% streptomycin and 2 mM L-glutamine. After 
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Table 1. Composition of low density array
Gene name
Collagen type I, alpha 1
Collagen type I, alpha 2




Procollagen-lysine 1, 2-oxoglutarate 5-dioxygenase 1
Procollagen-lysine 1, 2-oxoglutarate 5-dioxygenase 2
Procollagen-lysine 1, 2-oxoglutarate 5-dioxygenase 3
Glycosyltransferase 25 domain containing 1
Glycosyltransferase 25 domain containing 2
Bone morphogenetic protein 1
Procollagen C-endopeptidase enhancer
Procollagen C-endopeptidase enhancer 2
ADAM metalloproteinase with thrombospondin type 
1 motif, 2
ADAM metalloproteinase with thrombospondin type 
1 motif, 3
ADAM metalloproteinase with thrombospondin type 
1 motif, 14
Matrix metalloproteinase 1
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3 days of culture total RNA was isolated from the cells using the RNeasy 
Micro Kit (Qiagen, Hilden, Germany) according to the manufacturer’s 
protocol. Reverse transcription was carried out using the FirstStrandcD-
NA synthesis kit (Fermentas, St. Leon-Rot, Germany). Expression levels of 
genes known to be involved in collagen biosynthesis and homeostasis were 
analyzed with a custom made microfluidic card-based low density array 
(Table 1, Applied Biosystems, CA, USA) using the ViiATM7 Real-Time 
PCR System (Applied Biosystems). For each sample, 100 ng cDNA was 
diluted in 50 µl of distilled water and mixed with 50 µl of Taqman PCR 
master mix (Applied Biosystems). Standard recommended PCR protocols 
were performed (50°C for 2 minutes, 95°C for 10 minutes, and the next 
two steps were  repeated for 40 cycles: 95°C for 12 seconds and 60°C for 1 
minute). Relative mRNA levels were calculated as 2−ΔCT, in which ΔCT is 
CT value of target gene – CT value of GAPDH.  
Statistical analysis
All data are represented as means ± standard error of the mean of at 
least three independent experiments and were analyzed by one-way 
ANOVA followed by Tukey’s post hoc analysis test using GraphPad Prism 
Version 5 (GraphPad Software, Inc., La Jolla, USA). Values of p<0.05 were 




Characterization of amniotic fluid-derived cells 
Human amniotic fluid cells contained a heterogeneous cell population 
(containing cells with an epithelial and mesenchymal morphology) at the 
first passage. After five passages, all cells showed a mesenchymal phenotype. 
Cell populations derived from both healthy fetuses (H) and fetuses with 
a neural tube defect (NTD) showed a spindle-shaped morphology (Fig. 





























Figure 1. Characterization of amniotic fluid-derived cells. (A) Morphology of healthy and neural 
tube defect derived amniotic fluid cells. Original magnification 200x  (B) Percentage of positive 
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populations. For characterization, amniotic fluid-derived cells (AFCs) 
were analyzed by FACS for markers that are used for mesenchymal 
stem cell characterization. Both cell populations were negative (<4% 
positive cells) for hematopoietic markers CD34 and CD45 (Fig. 1B). 
Furthermore, healthy and NTD-AFCs were positive for mesenchymal 
markers CD44 (>98%) and CD90 (>65%) and embryonic stem cell 
markers SSEA4 (>70%) and Oct4 (>94%). The expression pattern of these 
markers indicates that both populations contain predominantly amniotic 
fluid derived-mesenchymal stem cells. No significant differences for all 6 
markers were detected between healthy and NTD AFCs, indicating that, 
based on these markers, a similar cell population can be isolated from 
healthy fetuses and fetuses with a neural tube defect. This suggests that 
NTD-AFCs might be used for fetal tissue engineering.  
Figure 2. Collagen type I deposition by human fetal dermal fibroblasts, healthy amniotic fluid cells 
and NTD amniotic fluid cells after TGF-β1 stimulation. COL1A1 protein staining on TGF-β1 
stimulated HDF-f, H-AFCs and NTD-AFCs for 3 days. Original magnification 200x.
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Collagen type I deposition by HDF-f, H-AFCs and NTD-AFCs after 
TGF-β1 stimulation
For skin tissue engineering, the formation of a new extracellular matrix 
(ECM) is a prerequisite. The most abundant ECM protein in fetal skin 
is collagen type I which is produced by fetal fibroblasts. To stimulate 
collagen deposition by fibroblasts the pro-fibrotic cytokine TGF-β1 can be 
used. We investigated whether TGF-β1 stimulation also increases collagen 
deposition by AFCs.  Collagen type I deposition was observed by HDF-f 
after 3 days of TGF-β1 stimulation (Fig. 2), as was the case with H-AFCs. 
However,  no collagen type I  was deposited by NTD-AFCs. These results 
indicate that NTD-AFCs fails to produce mature collagen type I.
Expression pattern of genes involved in collagen synthesis
Collagen biosynthesis is a complex process which involves numerous 
modifying, folding and processing enzymes. Differences in expression 
levels of these enzymes might give an explanation why NTD-AFCs are 
not able to deposit collagen I protein. We investigated the expression 
levels of genes that are involved in collagen biosynthesis and homeostasis 
of HDF-f, H-AFCs and NTD-AFCs with a custom made microfluidic 
card-based low density array.
Collagen synthesis starts intracellular with the synthesis of α-chains 
of pre-procollagen. Collagen type I is composed of a triple helix, which 
consists of two identical α1 chains (COL1A1) and one α2 chain (COL1A2). 
Healthy and NTD-AFCs show a similar expression of COL1A1 compared 
to HDF-f (Fig. 3A). However, expression of COL1A2 in NTD-AFCs was 
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HDF-f and h-AFCs, respectively).  Collagen type III is composed of a triple 
helix consisting of three α1 chains (COL3A1).  No significant differences 
were observed between HDF-f, H-AFCs and NTD-AFCs, although 
NTD-AFCs showed a 6-fold lower expression of COL3A1 compared 
to HDF-f and healthy AFCs. An important step of collagen synthesis 
is the 4-hydroxylation of proline residues to obtain 4-hydroxyproline, 
this step involves the enzymes prolyl 4-hydroxylase, alpha polypeptide 
(P4HA) 1, P4HA2 and P4HA3. No significant differences were found 
Figure 3. : Expression pattern of genes involved in collagen synthesis. Gene expression levels of 
(A) COL1A1, COL1A2 and COL3A1, (B) PLOD1, PLOD2, PLOD3, (C) BMP1, PCOLCE 
and PCOLCE2 and (D) ADAMTS2, ADAMTS3 and ADAMTS14 in HDF-f, H-AFCs and 
NTD-AFCs. *p < 0.05, ***p < 0.001.
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in the expression of these genes between all 3 cell types (data not shown). 
In collagen, certain lysine residues can be hydroxylated by procollagen-
lysine 1, 2-oxoglutarate 5-dioxygenase (PLOD) 1, PLOD2 and PLOD3 
to form hydroxylysine. No significant differences were found in PLOD1 
and PLOD2 expression levels, but PLOD3 is significantly lower expressed 
by NTD-AFCs compared to H-AFCs and HDF-f (Fig. 3B). Subsequently, 
some of the hydroxylysine residues can be glycosylated. Galactose can 
be added to the residues by glycosyltransferase 25 domain containing 1 
(GLT25D1) and GLTD25D2. No differences were found in the expression 
of these two genes between the cell types (data not shown). 
After hydroxylation of proline and lysine and glycosylation of 
hydroxyprolines, the three alpha chains assemble to form the triple 
helix resulting in procollagen. Next, procollagen is secreted and N- and 
C-propeptides are cleaved, to form mature collagen. Bone morphogenetic 
protein 1 (BMP1), also known as procollagen C proteinase, cleaves the 
C-propeptides of procollagen. No differences in BMP1 gene expression were 
found between HDF-f and AFCs (Fig. 3C). Procollagen C-endopeptidase 
enhancer proteins 1 and 2 (PCOLCE and PCOLCE2) are known to 
increase the catalytic activity of BMP1. PCOLCE is expressed by HDF-f 
and H-AFCs, but was not expressed by NTD-AFCs. PCOLCE2 is much 
lower expressed in NTD-AFCs and H-AFCs compared to HDF-f. The 
N-propeptides are cleaved off from procollagens by the metalloprotei-
nases ADAMTS2, ADAMTS3 and ADAMTS14. A significant lower 
expression of ADAMTS2 and ADAMTS14 (Fig. 3D) was observed in 
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in ADAMTS3 expression.  Overall, these results indicate that NTD-AFCs 
show  impaired synthesis and processing of collagen compared to H-AFCs.
Expression pattern of genes involved in collagen degradation
Another explanation that NTD-AFCs do not show collagen protein 
deposition might be that secreted collagen is quickly degraded by proteolytic 
enzymes. Therefore, we investigated the expression levels of enzymes 
that are involved in matrix degradation (Fig. 4). Matrix metalloprotein-
ase 1 (MMP1) expression is 10-fold lower in NTD-AFCs and 6.5 fold 
lower expressed in H-AFCs compared to HDF-f. The activity of MMPs 
can be inhibited by tissue inhibitor matrix metalloproteinase inhibitor 1 
(TIMP1). No differences were found in TIMP expression. Cathepsin K 
(CTSK) has been described to play a role in dermal ECM turnover [37;38]. 
Here we show that HDF-f and H-AFCs express CTSK, but that is not 
expressed by NTD-AFCs. 
These results indicate that the lack of collagen deposition by 
NTD-AFCs cannot be caused by an increased expression of enzymes with 

























































Figure 4. Expression pattern of genes involved in collagen degradation. Gene expression levels of 




Neurological damage of spina bifida has been explained by the two-hit 
hypothesis: the primary closure defect and subsequent secondary damage 
due to exposure of neural tissues [39-41]. Repair in utero, e.g. by tissue 
engineering techniques, can prevent this secondary damage caused by 
the exposure to the intra-uterine environment (e.g. the amniotic fluid). 
Several scaffolds have been used [5-11], in tissue engineering approaches 
for treatment of spina bifida, but always without the addition of AFCs. 
In a previous study, we showed that healthy AFCs can be used for skin 
tissue engineering [32]. It might be possible to use these healthy AFCs for 
allogeneic cell therapy to treat spina bifida, because the immature fetal 
immune system might be less susceptible to immune rejection. However, 
the only clinically successful in utero allogeneic stem cell therapy using 
hematopoietic stem cells has been carried out in severely immunologically 
compromised fetuses, suggesting that the fetal immune system plays an 
important role in the success of in utero stem cell therapy [42]. Therefore, 
autologous cell therapy is preferred. In the current study, we have 
investigated whether AFCs from NTD fetuses can be used as an autologous 
source for skin tissue engineering by analyzing their ability to produce 
collagen type I and therefore their capability of closing the defect. We 
stimulated NTD-AFCs with TGF-β1 (a cytokine that stimulates collagen 
production), and compared the collagen type I deposition with that of 
H-AFCs and HDF-f. Surprisingly, NTD-AFCs did not show any collagen 
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deposition after TGF-β1 stimulation. 
The etiology of spina bifida is multifactorial; both environmental and 
genetic factors play a role. So far, no mutations have been causally linked 
to spina bifida in humans. Folic acid deficiency due to nutrition problems 
is known to be associated with a higher incidence of spina bifida [43]. 
Furthermore, a number of pharmaceutical compounds can increase the risk 
of spina bifida [44;45]. The problem manifests itself already at the first month 
after fertilization. Since it is a highly localized defect, we expected that 
AFCs derived from these fetuses are normal, and that they can be used as 
an autologous cell source for tissue repair purposes. However, much to our 
surprise, the NTD-AFCs showed a markedly different expression of genes 
that are related to collagen synthesis compared to H-AFCs and HDF-f. 
No higher expression of enzymes that degrade collagen were found in 
NTD-AFCs, suggesting that collagen degradation cannot explain the lack 
of collagen type I deposition, but that there might be a defect in collagen 
synthesis and/or processing. Type I collagen is a heterotrimeric molecule 
composed of two α1 chains and one α2 chain. NTD-AFCs did not express 
COL1A2. In addition, NTD-AFCs had a much lower expression of genes 
(PCOLCE, PCOLCE2, ADAMTS2 and ADAMTS14) that are involved 
in the cleavage of propeptides from procollagen. Failure to remove the 
N- and C-terminal propeptides might result in a defective production of 
collagen fibrils. Despite the usage of AFCs in a variety of  studies, the 
current knowledge about the origin and function of these cells is limited. 
Therefore, it is hard to explain why NTD-AFCs show such a different 
expression pattern of genes that are involved in collagen biosynthesis.  
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In spina bifida, two different types of tissue are affected; the non-closure 
of the skin and the damaged neural tissue. In principle, both tissues can 
be repaired by the use of tissue engineering. Recently, in an experimental 
rat model for spina bifida [46] it has been shown that neural stem cells 
were present in amniotic fluid derived from NTD rat fetuses, but not in 
amniotic fluid from control fetuses. Although this has not been shown yet 
for humans, this could mean that even when NTD-AFCs are not able to 
produce collagen (not suitable for skin tissue engineering, i.e. closing the 
defect), these cells might still be used for tissue engineering to treat spina 
bifida in order to repair the neural tissue. 
In summary, we have shown that NTD-AFCs do not deposit collagen 
type I protein in vitro. This can be explained by a (much) lower expression 
of genes involved in collagen synthesis and processing of these cells 
compared to H-AFCs and HDF-f. These results suggest that autologous 
fetal therapy as treatment for spina bifida to close the defect might not be 
possible. 
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Background  Macrophages and fibroblasts are two major players in tissue 
repair and fibrosis. Despite the relevance of macrophages and fibroblasts 
in tissue homeostasis, remarkably little is known whether macrophages are 
able to influence the properties of fibroblasts. Here we investigated the role 
of paracrine factors secreted by classically activated (M1) and alternatively 
activated (M2) human macrophages on human dermal fibroblasts (HDFs).
Results    HDFs stimulated with paracrine factors from M1 macrophages 
showed a 10 to > 100-fold increase in the expression of the inflammatory 
cytokines IL6, CCL2 and CCL7 and the matrix metalloproteinas-
es MMP1 and MMP3. This indicates that factors produced by M1 
macrophages induce a fibroblast phenotype with pro-inflammatory and 
extracellular matrix (ECM) degrading properties. HDFs stimulated with 
paracrine factors secreted by M2 macrophages displayed an increased 
proliferation rate. Interestingly, the M1-activated pro-inflammatory 
fibroblasts downregulated, after exposure to paracrine factors produced by 
M2 macrophages or non-conditioned media, the inflammatory markers as 
well as MMPs and upregulated their collagen production. 
Conclusions Paracrine factors of M1 or M2 polarized macrophages 
induced different phenotypes of HDFs and the HDF phenotypes can in 
turn be reversed, pointing to a high dynamic plasticity of fibroblasts in the 
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Introduction
In wound healing and fibrosis, a variety of processes are crucial, such 
as inflammation, cell proliferation, cell migration and extracellular matrix 
(ECM) remodeling. Two major cellular players in these processes are 
macrophages and fibroblasts [1-4]. During the proliferation phase of wound 
healing, fibroblasts proliferate and migrate into the wound site to form 
granulation tissue. Part of these fibroblasts differentiate into myofibroblasts 
and produce new ECM, mainly in the form of collagen, which is necessary 
to support cellular ingrowth. The degradation of collagen in the wound is 
mainly controlled by matrix metalloproteinases (MMPs). In normal wound 
healing, most of the myofibroblasts and fibroblasts go into apoptosis in 
due time, or leave the wound site. However, in fibrosis myofibroblasts 
accumulate and produce an excess of collagen that remains deposited, 
thereby causing damage to the tissue architecture and diminishing its 
function [5-9].
The other important cell type in wound healing and fibrosis, 
macrophages, exist as resident tissue-specific macrophages, or are 
derived from circulating blood monocytes that undergo diapedesis and 
subsequently differentiate into macrophages. Macrophages display various 
activation states. The two opposite activation states are known as classically 
activated (M1) and alternatively activated (M2) macrophages [10,11]. The 
M1 macrophage is pro-inflammatory and is often associated with tissue 
injury and inflammation, whereas the M2 macrophage is associated with 
tissue repair and fibrosis [12-15]. Factors that induce the M1 polarization of 
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macrophages are interferon gamma (INFG), tumor necrosis factor (TNF), 
and/or lipopolysaccharides (LPS), whereas M2 macrophage polarization is 
induced by interleukin 4 (IL4), 13 (IL13), 10 (IL10), glucocorticoids and/
or transforming growth factor beta 1 (TGFβ1) [11,16,17].
In the inflammatory phase of wound healing, invading macrophages 
are pro-inflammatory (M1) and secrete several cytokines and chemokines, 
like chemokine (C-C motif ) ligand 2 (CCL2) (monocyte chemotactic 
protein-1), CCL7 (monocyte chemotactic protein-3) and interleukin 6 
(IL6). These cytokines/chemokines play a crucial role in wound healing 
and are involved in fibrogenesis [13,15,18-21]. M2 macrophages are associated 
with the healing process by modulating the inflammatory process and 
by secreting factors like CCL18. CCL18 is able to stimulate fibroblast 
proliferation and collagen production, which are important in the healing 
process, but an increased CCL18 expression can also induce fibrosis [22,23].
It has been shown that macrophages show a high dynamic 
plasticity. Macrophages can change, depending on the stimulus in the 
micro-environment, their secretion pattern of cytokines and chemokines 
several times [24-26]. For example, human primary M1 polarized macrophages 
can be re-polarized by secreted factors from their own counterparts, M2 
macrophages, and vice versa, in vitro[27]. In vivo, there are indications that 
re-polarization of macrophages also occurs, as shown in a mouse model for 
atherosclerosis [28] and in a rodent model for myocardial infarction [29]. This 
macrophage plasticity not only has an effect on the inflammation phase of 
wound healing, but likely also on the proliferation and remodeling phase.
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homeostasis, remarkably little is known whether the different types of 
human primary macrophages are able to influence directly the properties 
of human primary fibroblasts. Most of the data found in literature have 
generally been generated with cell lines [30-32] or primary cells from murine 
origin[33,34], mostly without paying attention to the M1/M2 activation 
state. Here we investigated the role of paracrine factors secreted by human 
M1 and M2 macrophages on primary adult human dermal fibroblasts 
(HDFs) with respect to proliferation, myofibroblast formation, collagen 
synthesis and degradation, as well as synthesis of various cytokines. Because 
of the plasticity of macrophages, we also set out to investigate the influence 
of paracrine factors secreted by M1 macrophages followed by paracrine 
factors secreted by M2 macrophages on HDFs.
 
Materials and methods
Isolation of CD14+ cells
Human peripheral blood mononuclear cells (PBMCs) from healthy 
donors were isolated from buffy coats (Sanquin, Groningen, the 
Netherlands) by density-gradient centrifugation using Lymphoprep 
(Axis-Shield, Oslo, Norway) according to the manufacturer’s protocol. 
Briefly, blood was diluted three times with isolation buffer (pH 7.4) 
consisting of phosphate buffered saline (PBS) with 0.5% fetal bovine 
serum (FBS; Life Technologies Europe BV, Bleiswijk, the Netherlands) 
and 2 mM EDTA (Merck, Darmstadt, Germany). This mixture (30 ml) 
was layered over 20 ml of Lymphoprep and centrifuged at 800 × g for 
30 min. Residual erythrocytes were lysed on ice (10 min) in 155 mM 
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NH4Cl, 10 mM KHCO3, 0.1 mM EDTA (pH 7.4) and the suspension 
was centrifuged at 300 × g at 4°C for 10 min after which the supernatant 
was discarded and the pellet gently resuspended in isolation buffer. 
PBMCs were counted using a Coulter Counter (Beckman Coulter, Inc. 
Brea, USA).
CD14+ cells were isolated by immunomagnetic bead separation using 
CD14 Microbeads (Miltenyi Biotec B.V., Leiden, the Netherlands). 
Briefly, 1 × 107 PBMCs were labeled with 20 µl CD14 Microbeads and 
incubated on ice in 80 µl isolation buffer for 30 min. Cells were washed 
with isolation buffer and the suspension was centrifuged at 300 × g at 
4°C for 10 min. The pellet was resuspended in degassed isolation buffer 
and the CD14+ cells were separated with an LS column (Miltenyi Biotec 
B.V., Leiden, the Netherlands) placed on a column adapter in a strong 
magnetic field. CD14+ cells bind to the column and after carefully washing 
with degassed isolation buffer and removal of the LS column from the 
magnet the CD14+ cells were flushed out from the column using a 
plunger. The CD14+ cells were counted with a Coulter Counter and after 
centrifugation at 300 × g for 10 min at 4°C gently resuspended in culture 
medium, consisting of X-VIVO-10 medium (Lonza, Basel, Switzerland) 
supplemented with 2 mM l-glutamine (Sigma-Aldrich, St. Louis, USA), 
1% penicillin/streptomycin (Sigma-Aldrich, St. Louis, USA) and 10 ng/




Cell plasticity in wound healing
Macrophage cell culture, polarization with M1 or M2 stimuli and collection 
of conditioned media
Immediately after isolation and counting, the cell suspension was plated 
with a density of 100,000 cells/ cm2 onto tissue culture polystyrene plates 
(TCPS; Corning Incorporated, NY, USA). Cells were cultured at 37°C 
under 5% CO2. Cells were refed at day 3 and non-attached cells were 
removed from culture at day 6.
At day 6, the adherent cells (macrophages) were washed and stimulated 
in culture medium (but without M-CSF), with either (1) 1 µg/ml LPS 
(Sigma-Aldrich, St. Louis, USA) + 10 ng/ml IFNG (PeproTech, Rocky 
Hill, USA) (classical stimuli), (2) 2 ng/ml IL4 + 2 ng/ml IL13 (both R&D, 
Minneapolis, USA) (alternative stimuli), or (3) no stimulation (control) at 
37°C for 48 h. The polarization state of the macrophages was determined 
by quantitative RT-PCR (qRT-PCR). The cells were subsequently washed 
and cultured in X-VIVO-10 medium for 4 h (conditioned medium). After 
4 h the CM from (1) M1 macrophages, (2) M2 macrophages and (3) 
unstimulated macrophages was collected and stored for further analyses 
at −20°C. The CM of the different conditions were used for stimulation 
of HDFs, the determination of CCL2 and CCL18 levels by means of 
enzyme-linked immunosorbent assays (ELISA) and the determination of 
cytokines with a multiplex bead immunoassay.
HDF cell culture and stimulation with CM of M1, M2 and unstimulated 
macrophages
Primary HDFs (#2320, ScienCell, Carlsbad, USA) were seeded onto 
TCPS overnight with a density of 15,000 cells/cm2 in X-VIVO-10 medium 
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containing 2 mM l-glutamine, 1% penicillin/streptomycin and 50 µg/ml 
l-ascorbic acid 2-phosphate sesquimagnesium salt hydrate (Sigma-Aldrich, 
St. Louis, USA). The next day the X-VIVO medium was replaced by CM 
derived of M1, M2 or unstimulated macrophages, which was supplemented 
with l-ascorbic acid 2-phosphate sesquimagnesium salt hydrate. Passage 5 
or 6 of HDFs were used for stimulations with CM from macrophages. The 
CM was refreshed every day and the stimulated HDFs were characterized 
at 24 h, 48 h, 72 h and 144 h by morphology, qRT-PCR and after 24 h, 
72 h and 144 h by immunofluorescent stainings. The deposition of the 
extracellular matrix protein collagen type I was determined at 72 h and 
144 h. After 24 h and 48 h, CM of stimulated HDFs was collected and 
stored for further analysis at −20°C. Prior to collection of the CM, the 
stimulated HDFs were washed and cultured in X-VIVO-10 medium for 
4 h. CCL2, CCL7, IL6, MMP1, MMP2 and MMP3 secretion by HDFs 
was determined by ELISA. All culture conditions were carried out at 37°C 
under 5% CO2.
Stimulation of HDFs by CM of M1 macrophages followed by stimulation 
with CM of M2 macrophages (switch)
HDFs were cultured as described above. After overnight seeding in 
X-VIVO-10 medium the medium was replaced by CM of M1 macrophages 
for 24 h or 48 h, with refreshment of the CM after 24 h. After 24 h or 48 
h the medium was replaced by CM of M2 macrophages or by X-VIVO-10 
medium (non-CM) for another 48 h or 96 h, respectively (total culture 
time now 72 h and 144 h, respectively); the CM or non-CM were refreshed 
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RNA isolation, cDNA synthesis and qRT-PCR
Total RNA was isolated from the cells using the RNeasy Kit (Qiagen 
Inc., CA, USA) in accordance to the manufacturer’s protocol. RNA 
concentration and purity were determined by UV spectrophotometry 
(NanoDrop Technologies, Wilmington, NC). For qRT-PCR analysis, total 
RNA was reverse transcribed using the First Strand cDNA synthesis kit 
(Fermentas UAB, Lithuania) in accordance to the manufacturer’s protocol. 
Quantification of gene expression was performed using qRT-PCR analysis 
in a final reaction volume of 10 µl, consisting of 1× SYBR Green Supermix 
(Bio-Rad, Hercules, USA), 6 µM forward primer, 6 µM reverse primer 
(Table 1) and 5 ng cDNA. Reactions were performed at 95°C for 15 sec, 
60°C for 30 sec, 72°C for 30 sec, for 40 cycles in a ViiA™ 7 Real-Time 
PCR System (Applied Biosystems, CA, USA). Analysis of the data was 
performed using ViiA 7™ Real-Time PCR System Software v1.1 (Applied 
Biosystems, CA, USA).
Enzyme-linked immunosorbent assay (ELISA)
Determination of CCL2, CCL7, CCL18, IL6, MMP1, MMP2 and 
MMP3 protein levels were measured using DuoSet® ELISA Development 
kit (R&D Systems, Minneapolis, USA) in accordance to manufacturer’s 
protocol. Briefly, 96 wells plates (#9018, Corning, Amsterdam, The 
Netherlands) were coated with Capture Antibody and incubated overnight 
at room temperature (RT). After incubation the plates were washed with 
0.05% Tween-20 (Sigma-Aldrich, St. Louis, USA) in PBS and blocked with 
1% bovine serum albumin (BSA) (Sanquin, Amsterdam, the Netherlands) 
114
Chapter 5







































































Cell plasticity in wound healing
in PBS for 1 h. After washing, the plates were incubated with diluted sample 
or matched standards for 2 h. The detection was performed using matched 
biotin conjugated antibodies followed by streptavidin-poly-horseradish 
peroxidase (Sanquin, Amsterdam, The Netherlands). The color reaction 
was performed with tetramethylbenzidine (TMB; Sigma-Aldrich, St. 
Louis, USA) in sodium acetate buffer, pH 6, containing H2O2 and stopped 
with 1 M H2SO4. The absorbance was measured using a microplate reader 
(VERSA max, Molecular Devices Inc., CA, USA). The detection limit for 
MMP2, MMP1, MMP3, CCL2, IL6, CCL7 and CCL18 was 312 pg/ml, 
78 pg/ml, 15.6 pg/ml, 7.8 pg/ml, 4.7 pg/ml and 3.9 pg/ml, respectively.
Multiplex bead immunoassay
Factors that were secreted by M1, M2 and unstimulated macrophages 
were determined by a multiplex bead immunoassay in accordance to 
manufacturer’s protocol (Invitrogen Corporation, Carlsbad, USA). 
Briefly, beads that have defined spectral properties and are conjugated to 
protein-specific capture antibodies were added to a 96 well filter plate. 
After washing, the plate was incubated with sample or matched standards 
for 2 h. The detection was performed using protein-specific biotinylated 
detector antibodies and streptavidin conjugated R-Phycoerythrin. The 
beads were analyzed with the Luminex-100 detection system (Luminex, 
Austin, USA).
Proteolytic activity assay
MMP activity was determined in the CM of HDFs after 24 h of 
stimulation with CM derived of M1, M2 or unstimulated macrophages. 
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The CM of the HDFs was mixed, in a black 96 flat bottom plate, 
with prewarmed assay buffer containing 0.1 M 4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid (HEPES), 20 mM CaCl2, 0,1% Brij-35, 
pH 7.0 and 10 µM OmniMMP™ fluorogenic substrate (BML-P126, 
Enzo Life Sciences, Antwerpen, Belgium). The fluorescent intensity was 
measured using a fluorescence plate reader (BIO-TEK FL600, BIO-TEK 
instruments, Inc., Winooski, USA) after 20 h of incubation at 37°C.
Immunofluorescent stainings for ACTA2 and MKI67 on stimulated adult 
human dermal fibroblasts
After 24 h and 144 h of culture, HDFs were washed twice with PBS 
and fixed in 2% paraformaldehyde (PFA) at RT for 10 min. Fixed cells 
were incubated with 0.5% Triton X-100 (Merck, Darmstadt, Germany) in 
PBS for 3 min at RT. After washing with PBS the cells were incubated with 
(1) mouse-anti-human ACTA2 (M0851, Dako, Glosstrup, Denmark) 
(1:100) or (2) rabbit-anti-human MKI67 (MONOSAN®, Uden, The 
Netherlands) (1:500) diluted in PBS containing 1% BSA for 1 h at RT. 
After three washes with PBS, cells were incubated with biotinylated 
(1) goat-anti-mouse IgG2a-biotin (SouthernBiotech, Alabama, USA) 
(1:100), or (2) goat-anti-rabbit-FITC (SouthernBiotech, Alabama, USA) 
(1:100) diluted in PBS containing 2% normal human serum (NHS) for 
30 min at room temperature. The cells were subsequently washed three 
times with PBS and incubated with streptavidine-CY3 (Invitrogen, Grand 
Island, USA) (1:100) in PBS containing 1% BSA, 2% NHS and DAPI 
(1:5000) for 30 min. After three washes with PBS the slides were mounted 
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cent microscopy using a Leica DMRA microscope equipped with a Leica 
DFC350FX digital camera and Leica Application Suite (LAS) software (all 
Leica Microsystems, Wetzlar, Germany).
Collagen type I deposition by HDFs after stimulation with CM of M1, M2 
or unstimulated macrophages
After 72 h and 144 h of culture, HDFs were washed twice with PBS 
and fixed in 2% PFA at RT for 10 min. Fixed cells were incubated at RT 
with (1) mouse-anti-human collagen type I (COL I) (1:100) (ab90395, 
Abcam, Cambridge, UK) diluted in PBS containing 1% BSA for 1h. The 
HDFs were washed three times with PBS, followed by incubation with 
goat-anti-mouse IgG1-biotin (SouthernBiotech, Alabama, USA) (1:100) 
diluted in 1% BSA in PBS for 30 min. The cells were subsequently washed 
three times with PBS and incubated with streptavidine-CY3 (1:100) in 
PBS containing 1% BSA, 2% NHS and DAPI (1:5000) for 30 min. After 
three washes with PBS the slides were mounted in Citifluor and examined 
by immunofluorescent microscopy using a Leica DMRA microscope.
Collagen gel contraction
Collagen gels were prepared by mixing X-VIVO-10 medium, 1 
M NaOH, 10 × PBS, 0.2 M HEPES and collagen I (BD Biosciences, 
Franklin Lakes, NJ USA). The final concentration was 5.2 mM NaOH, 
1 × PBS, 2 mM HEPES, 2.4 mg/ml of collagen I in X-VIVO-10 
medium. HDFs were added in a concentration of 200.000 cells/ml and 
500 µl of this mixture was pipetted into a well of a 24-well culture plate. 
Polymerization of the solution occurred within 1h at 37°C under 5% 
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CO2. After polymerization CM of M1, M2 or unstimulated macrophages 
was added. As control complete X-VIVO medium supplemented with 10 
ng/ml TGFB1 (PeproTech EC Ltd, London, UK) was used. The CM and 
medium supplemented with TGFB1 was refreshed every day and the cells 
were cultured at 37°C under 5% CO2. After 5 days the gels were gently 
released and contractile force was analyzed by measuring the gel diameter 
at 8 h after release using a flatbed scanner (Hewlett-Packard Company, 
Palo Alto, USA) Data are expressed as the percentage of area compared to 
the initial gel area.
Statistics
All data are represented as means ± standard error of the mean of at least 
three independent experiments and were analyzed by Graph-Pad Prism 
Version 5 for Macintosh (GraphPad Software, Inc., La Jolla, CA, USA) 
either by one-way ANOVA followed by Tukey’s post hoc analysis, or by 
two-way ANOVA followed by Bonferroni post hoc analysis. Values of P < 
0.05 were considered to be statistically significant.
Results
Characterization of macrophages after M1 or M2 polarization
Primary human macrophages responded to LPS/IFNG or IL4/
IL13, resulting in M1 or M2 polarization, respectively. M1 polarized 
macrophages adopted a “dendritic”-like morphology with large filopodia 
while M2 polarized macrophages showed a rounded and/or spindle-shaped 
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macrophages (Figure 1A).
The three macrophage subsets showed compared to the reference gene 
tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation 
protein, zeta polypeptide (YWHAZ), a high expression of CD68, which 
is a general marker for macrophages. M1 macrophages had a lower CD68 
expression than M2 polarized or unstimulated macrophages (Figure 1B). 
CD14, a co-receptor for toll-like receptor 4 (TLR4), is involved in LPS 
recognition and is upregulated by M1 polarized macrophages compared to 
M2 or unstimulated macrophages (Figure 1B).
Macrophages stimulated for 48 h with LPS/IFNG showed an 
upregulation of the inflammatory genes interleukin 1 beta (IL1B), IL6 and 
CCL2 compared to M2 polarized and unstimulated macrophages (Figure 
1C). A similar upregulation of CD40, a protein involved in the activation 
of antigen presenting cells, was seen after LPS/IFNG stimulation (Figure 
1C).
Macrophages stimulated with IL4/IL13 showed an upregulated gene 
expression of C-type lectin domain family 10, member A (CLEC10A; 
also known as macrophage galactose N-acetyl-galactosamine specific 
lectin) and mannose receptor, C type 1 (MRC1) compared to M1 
polarized or unstimulated macrophages. CCL18 tended to be upregulated 
in IL4/IL13 stimulated macrophages while interleukin 1 receptor, type 
II (IL1R2), which acts as a decoy receptor for the type I interleukin 1, 
showed a higher expression in IL4/IL13 and unstimulated macrophages 
than M1 polarized macrophages (Figure 1D). M1 macrophages 
secreted significantly more CCL2 compared to M2 and unstimulated 
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Figure 1. Characterization of macrophages after M1 or M2 polarization. After stimulation with 
LPS/IFNG, M1 macrophages showed a dendritic morphology while IL4/IL13 (M2) stimulated 
and unstimulated macrophages  showed a rounded and/or spindle-shaped morphology (A). 
The three primary macrophages subsets showed, compared to reference gene YWHAZ, a high 
expression of CD68. In M1 polarized macrophages the CD68 gene expression is downregulat-
ed while the expression of CD14 is upregulated compared to M2 or unstimulated macrophages 
(B). LPS/IFNG-stimulated (M1) macrophages showed upregulated gene expression of IL1B, IL6, 
CCL2 and CD40 (C). IL4/IL13-stimulated (M2) macrophages upregulated the gene expression of 
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macrophages. M2 and M1 macrophages secreted more CCL18 compared 
to unstimulated macrophages, but no significant differences in secretion 
were seen between M1 and M2 (Figure 1E). M1 macrophages secreted 
more pro-inflammatory cytokines and chemokines compared to M2 and 
unstimulated macrophages (Table 2). M2 macrophages secreted fibroblast 
growth factor 2 (FGF2), which was significant different compared to M1 
and unstimulated macrophages (Table 2).
Overall, our results indicate that M1 polarized macrophages were 
pro-inflammatory while M2 polarized macrophages were non-inflammatory 
and unstimulated macrophages adopted a M2 “intermediate” phenotype.
Morphology of HDFs stimulated with conditioned medium (CM) of M1 
polarized, M2 polarized, or unstimulated macrophages
Dermal fibroblasts were stimulated with CM of M1 polarized, M2 
polarized or unstimulated macrophages for 24 h, 48 h, 72 h and 144 
h. After 24 h of stimulation, the fibroblasts showed a spindle-shaped 
morphology in all three conditions (Figure 2A, B, C). After 24 h of 
stimulation with CM of M1 macrophages some rounded fibroblasts were 
seen, which were not present in the fibroblast cultures stimulated with 
CM of M2 polarized or unstimulated macrophages (Figure 2A). After 48 
h of stimulation, the morphology of the fibroblasts was similar to that of 
unstimulated macrophages and was downregulated in M1 polarized macrophages (D). At protein 
level, more CCL2 was observed in conditioned medium from M1 macrophages. CCL18 protein 
secretion showed, like CCL2, values that correlated with gene expression (E). * p < 0.05, Difference 
between LPS/IFNG and IL4/IL13 stimulated macrophages, ** p < 0.01, *** p < 0.001. # p < 0.05, 
Difference between LPS/IFNG stimulated and unstimulated macrophages, ### p < 0.001. ^^ p < 
0.01, Difference between IL4/IL13 stimulated and unstimulated macrophages. Data were analyzed 
using one-way ANOVA followed by Tukey’s post-test. Gene expression analysis n = 4, protein 
secretion n = 3. 
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24h of stimulation (data not shown). However, the fibroblast morphology 
changes in time. CM of M1 macrophages induced a rounded morphology, 
which was clearly seen after 72 h (Figure 2D) and 144 h (Figure 2G), while 
fibroblasts stimulated with CM of M2 macrophages adopted an elongated 
spindle-shaped cell morphology after 72 h and 144 h (Figure 2E, and 
H). The morphology of fibroblasts stimulated with CM of unstimulated 
macrophages had a spindle-shaped morphology after 72 h and 144 h 
(Figure 2F and I) that was similar to 24 h (Figure 2C). This morphology 
was also seen by fibroblasts cultured in control medium (data not shown).
Table 2. Overview secreted cytokines, chemokines and growth factors by different polarized 
macrophages



























































































Cell plasticity in wound healing
CM from M1 macrophages induces a pro-inflammatory HDF
HDFs showed, after stimulation with CM of M1 macrophages, a > 
10-fold increase in the expression of the pro-inflammatory gene CCL2 
compared to fibroblasts stimulated with CM of M2 or unstimulated 
macrophages at all time points (Figure 3A). The expression of the 
pro-inflammatory genes IL6 and CCL7 was > 100-fold upregulated at 
all time points by fibroblasts stimulated with CM of M1 macrophages 
Figure 2. Morphology of HDFs stimulated with CM of M1 polarized, M2 polarized, or unstimu-
lated macrophages. HDFs stimulated with CM of M1 polarized macrophages; 24 h (A), 72 h (D), 
and 144 h (G). After 24 h, most of the fibroblasts showed a spindle-shaped morphology although 
some rounded fibroblasts were seen. After 72 h, the fibroblasts adopted a rounded morphology that 
was most prominent after 144 h. HDFs stimulated with CM of M2 polarized macrophages; 24 
h (B), 72 h (E) and 144 h (H). After 24 h the cells showed a spindle-like morphology, which was 
changed into an elongated spindle-like morphology after 72 h. HDFs stimulated with CM from 
unstimulated macrophages 24 h (C), 72 h (F), and 144 h (I). The fibroblasts showed a spindle-like 
morphology after 24 h, which was not changed in time.
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compared to fibroblasts stimulated with CM of M2 or unstimulated 
macrophages (Figure 3A).
Secretion of the cytokines CCL2, IL6 and chemokine CCL7 by 
dermal fibroblasts was determined after 24 h and 48h of stimulation. 
Fibroblasts stimulated with CM of M1 macrophages secreted significantly 
more CCL2 and IL6 compared to fibroblasts stimulated with CM of M2 
macrophages or unstimulated macrophages after 24 h and 48 h (Figure 
3B). Secretion of CCL7 by M1 CM stimulated fibroblasts was higher 
after 24 h and becomes significant after 48 h of stimulation compared to 
Figure 3. CM from M1 macrophages induces a pro-inflammatory HDF. HDFs upregulated the 
gene expression of pro-inflammatory genes CCL2, IL6 and CCL7 after stimulation with CM of 
M1 polarized macrophages compared to M2 polarized and unstimulated macrophages (A). HDFs 
stimulated with CM of M1 macrophages secreted significantly more CCL2, IL6 and CCL7 after 
24 h and 48 h, whereas secretion levels of these proteins by fibroblasts stimulated with CM of 
M2 macrophages or unstimulated macrophages were below the detection limit (B). ** p < 0.01, 
Difference between HDFs stimulated with CM of M1 polarized and CM of M2 polarized 
macrophages, *** p < 0.001. # p < 0.05, Difference between HDFs stimulated with CM of M1 
polarized and CM of unstimulated macrophages, ## p < 0.01, ### p < 0.001. Gene expression 
analysis data were analyzed using two-way ANOVA followed by Bonferroni’s post-test, n = 4. 
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Figure 4. CM from M1 macrophages induces dermal fibroblasts with extracellular matrix 
degradation properties. HDFs upregulated the gene expression of MMP1, MMP2, MMP3, 
MMP14 and TIMP1 after stimulation with CM of M1 polarized macrophages compared to M2 
polarized and unstimulated macrophages (A). HDFs stimulated with CM of M1 macrophages 
secreted significantly more MMP1, MMP2 and MMP3 protein compared to fibroblasts stimulated 
with CM of M2 macrophages or unstimulated macrophages (B). HDFs stimulated with M1 
CM showed a higher net proteolytic activity compared to HDFs stimulated with CM of M2 and 
unstimulated macrophages (C). ** p < 0.01, Difference between HDFs stimulated with CM of M1 
polarized and CM of M2 polarized macrophages, *** p < 0.001. ## p < 0.01, Difference between 
HDFs stimulated with CM of M1 polarized and CM of unstimulated macrophages, ### p < 0.001. 
Gene expression analysis data were analyzed using two-way ANOVA followed by Bonferroni’s 
post-test, n = 4. MMP secretion was analyzed using one-way ANOVA followed by Tukey’s post-test, 
n = 3. Proteolytic activity was analyzed using one-way ANOVA followed by Tukey’s post-test, n = 4.
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fibroblasts stimulated with M2 or unstimulated macrophages CM (Figure 
3B). These results are in accordance with the gene expression patterns of 
the stimulated fibroblasts.
The results indicate that M1 macrophages induce, by means of paracrine 
signaling, a pro-inflammatory dermal fibroblast.
CM from M1 macrophages induces the expression of ECM degrading 
enzymes by HDFs
Stimulation of dermal fibroblasts with CM of M1 macrophages already 
showed an upregulated gene expression of MMP1, MMP2, MMP3 
and MMP14 compared to the other conditions after 24 h (Figure 4A). 
These MMP gene expression profiles were consistently upregulated 
over time, except for MMP2 and MMP14 after 144 h. Tissue inhibitor 
of metalloproteinases −1 (TIMP1) was also upregulated (2–3 fold) in 
fibroblasts stimulated with CM of M1 macrophages, but the total MMP 
gene expression levels were much higher upregulated: MMP1 and MMP3 
were > 10 and > 100 fold upregulated, respectively (Figure 4A). On protein 
level, the secretion of MMP1, MMP2 and MMP3 were upregulated by 
fibroblasts after stimulation with CM of M1 macrophages in the same 
order of magnitude as observed by the respective expression data (Figure 
4B). Indeed, the secreted MMPs showed a higher net proteolytic activity 
compared to medium derived from fibroblasts stimulated with CM of M2 
or unstimulated macrophages (Figure 4C).
The results indicate that fibroblasts subjected to factors produced by 
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Figure 5. CM of M1 polarized, M2 polarized or unstimulated macrophages do not induce 
myofibroblast differentiation of HDFs. HDFs stimulated with CM of unstimulated macrophages 
showed, compared to fibroblasts stimulated with CM of M1 polarized macrophages, an upregulated 
gene expression of ACTA2 after 48 h, 72 h and 144 h. HDFs stimulated with CM of M2 polarized 
macrophages showed a higher gene expression of ACTA2 compared to HDFs stimulated with CM 
of M1 macrophages after 144 h (A). No differences were observed in TAGLN gene expression 
between the three conditions in all time points (A). No differences in ACTA2 protein expression 





positive control (B). Fibroblasts stimulated with CM of M1 macrophages contract the collagen 
10% more than fibroblasts stimulated with CM of M2 and unstimulated fibroblasts. Fibroblasts 
stimulated with TGFB1 contract the collagen 50% more compared to the other stimulations 
(C). * p < 0.05, Difference between HDFs stimulated with CM of M1 polarized and CM of M2 
polarized macrophages, *** p < 0.001. # p < 0.05, Difference between HDFs stimulated with 
CM of M1 polarized and CM of unstimulated macrophages, ## p < 0.01, ### p < 0.001. ^ p 
< 0.05, Difference between HDFs stimulated with CM of M2 polarized and CM of unstimu-
lated macrophages. ≅≅≅ p < 0.001, Difference between HDFs stimulated with TGFB1 and 
CM of M1 polarized macrophages. §§§ p < 0.001, Difference between HDFs stimulated with 
TGFB1 and CM of M2 polarized macrophages. ❖❖❖ p < 0.001, Difference between HDFs 
stimulated with TGFB1 and CM of unstimulated polarized macrophages. Gene expression analysis 
data were analyzed using two-way ANOVA followed by Bonferroni’s post-test, n = 4. ACTA2 
protein expression was shown in red and nuclei in blue (DAPI), original magnification 200x. 
Collagen gel contraction analysis data were analyzed using one-way ANOVA followed by Tukey’s 
post-test, n = 3.  
Figure 6. Proliferation of HDFs is induced by CM of M2 macrophages. After 72 h, no differences 
in cell numbers were seen between HDFs stimulated with CM of M1 polarized, M2 polarized or 
unstimulated macrophages. After 144 h, stimulation with CM of M2 macrophages increased the 
dermal fibroblast cell number, exclusively (A). This is due to proliferation of the HDFs as shown by 
MKI67 protein staining (B). More MKI67 positive nuclei (green) were seen in fibroblasts stimulated 
with CM of M2 macrophages compared to fibroblasts stimulated with CM of M1 and unstimu-
lated macrophages after 144 h (C). *** p < 0.001, Difference between HDFs stimulated with CM 
of M1 polarized and CM of M2 polarized macrophages. # p < 0.05, Difference between HDFs 
stimulated with CM of M2 polarized and CM of unstimulated macrophages. ^  p < 0.05, Difference 
between 72 h and 144 h after stimulation of HDFs with CM of M2 polarized macrophages. Cell 
numbers and MKI67 positive nuclei were analyzed using two-way ANOVA followed by Bonfer-
roni’s post-test n = 3. MKI67 protein expression was shown in green, nuclei in blue (DAPI) and 
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Figure 7. Influence of CM of M1 polarized, M2 polarized or unstimulated macrophages on extracel-
lular matrix deposition by fibroblasts. After 144 h, HDFs stimulated with CM of M1 macrophages 
showed reduced COL1A1 and COL3A1 gene expression levels compared to stimulation with 
CM of M2 and unstimulated macrophages (A). No differences in COL1A1 deposition by 
fibroblasts were seen after the three different stimulations after 72 h. However, less collagen type 
I protein deposition was seen in fibroblasts stimulated with CM of M1 macrophages compared 
to stimulation with CM of unstimulated macrophages after 144 h (B). ** p < 0.01, Difference 
between HDFs stimulated with CM of M1 polarized and CM of M2 polarized macrophages. ## p 
< 0.01, Difference between HDFs stimulated with CM of M1 polarized and CM of unstimulated 
macrophages. Gene expression analysis data were analyzed using two-way ANOVA followed by 
Bonferroni’s post-test, n = 4. COL1A1 protein expression was shown in red, nuclei in blue (DAPI) 
and original magnification was 200×.
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CM of M1 polarized, M2 polarized or unstimulated macrophages does 
not induce myofibroblast differentiation of HDFs
Alpha-actin-2 (ACTA2; also known as alpha Smooth Muscle Actin), 
a marker for myofibroblast formation, is upregulated at gene expression 
level by fibroblasts stimulated with CM of unstimulated macrophages 
compared to CM of M1 stimulated macrophages after 48 h, 72 h and 
144 h. Fibroblasts stimulated with CM of M2 macrophages showed 
an upregulation of ACTA2 compared to fibroblasts stimulated with 
CM of M1 macrophages after 144 h (Figure 5A). No differences were 
observed in transgelin (TAGLN) (smooth muscle protein 22-alpha) gene 
expression, a calponin that is mainly expressed by smooth muscle cells and 
myofibroblasts (Figure 5A).
On protein level no ACTA2 was seen in fibroblasts after 144 h of 
stimulation with the three different CM. This was in contrast to TGFB1 
stimulated fibroblasts (myofibroblasts), which showed ACTA2 protein 
expression after 144 h (Figure 5B). TGFB1 stimulated fibroblasts showed 
a higher contractile force compared with fibroblasts stimulated with 
CM of different macrophages in a collagen gel contraction assay (Figure 
5C). Fibroblasts stimulated with CM of M1 macrophages contract the 
collagen gel slightly more than fibroblasts stimulated with CM of M2 and 
unstimulated fibroblasts. It is reported by Zhu et al. that active MMPs 
increases collagen gel contraction [35,36]. It is likely that the secretion of 
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Together, these results indicate that CM from M1, M2 or unstimulated 
macrophages did not result in the differentiation of fibroblasts into 
myofibroblasts.
Proliferation of HDFs is induced by CM of M2 macrophages
After 72 h, fibroblast cell numbers were similar in all conditions, but 
increased exclusively after stimulation with CM of M2 macrophages after 
144 h (Figure 6A). Nuclear protein Ki-67 (MKI67), a cellular marker for 
proliferation, showed the same amount of positive nuclei at 24 h in all 
conditions. This indicates that a comparable proliferation rate occurs at 
24 h (Figure 6B). At 144 h, more MKI67 positive nuclei were seen when 
fibroblasts were stimulated with CM of M2 macrophages compared to CM 
from M1 or unstimulated macrophages, although in all three conditions 
positive nuclei were seen (Figure 6B and C).
The results indicate that CM from M2 macrophages induced 
proliferation of fibroblasts.
Influence of CM of M1 polarized, M2 polarized or unstimulated 
macrophages on extracellular matrix deposition by HDFs
ECM deposition by fibroblasts is an important process in wound 
healing and fibrosis. Two major collagens produced in these processes are 
collagen type I (COL1A1) and collagen type III (COL3A1). COL1A1 
gene expression in fibroblasts was reduced after stimulation with CM of 
M1 macrophages compared to CM of M2 and unstimulated macrophages 
after 144 h (Figure 7A). CM of M1 macrophages reduced COL3A1 gene 
expression in fibroblasts compared to CM of M2 macrophages at 144 h 
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Figure 8. Fibroblasts stimulated with CM of M1 macrophages followed by stimulation with CM of 
M2 macrophage or non-CM (switch). When stimulation of HDFs with CM of M1 macrophages is 
followed by CM of M2 macrophages or non-CM (switch), the pro-inflammatory genes CCL2 and 
IL6 were completely downregulated and showed the same gene expression as fibroblasts stimulated 
with only CM of M2 macrophages after 72 h and 144 h (A). MMP1 gene expression after the CM 
switch was downregulated at 144 h, whereas TIMP1 expression remained similar (B). COL1A1 
gene expression was upregulated after the CM switch compared to fibroblasts stimulated with 
CM of M1 macrophages at 144 h. This gene expression level was similar to fibroblasts stimulated 
with CM of M2 macrophages (C). After the switch no differences were seen in COL3A1 gene 
expression compared fibroblasts stimulated with CM of M1 or CM of M2 macrophages (C). * p 
< 0.05, Difference between HDFs stimulated with CM of M1 polarized and CM of M2 polarized 
macrophages, ** p < 0.01, *** p < 0.001. §§ p < 0.01, Difference between HDFs stimulated with 
CM of M1 polarized and the switch to non-CM, §§§ p < 0.001. # p < 0.05, Difference between 
HDFs stimulated with CM of M1 polarized and the CM switch, ### p < 0.001. ≅≅ p < 0.01, 
Difference between HDFs stimulated with CM of M2 polarized and the switch to non-CM, ≅≅≅ 
p < 0.001. ^  p < 0.05, Difference between HDFs stimulated with CM of M2 polarized and the CM 
switch. Gene expression analysis data were analyzed using two-way ANOVA followed by Bonfer-
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(Figure 7A). No difference in COL1A1 and COL3A1 gene expression was 
seen in fibroblasts stimulated with CM of M2 or unstimulated macrophages 
compared to fibroblasts cultured in control medium (data not shown).
After 72 h, no difference in collagen type I deposition was seen after 
the different stimulations. However, less collagen type I protein deposition 
was seen by fibroblasts stimulated with CM of M1 macrophages compared 
to the other conditions after 144 h (Figure 7B). These results are in 
accordance with the gene expression patterns of the stimulated fibroblasts.
The results indicate that CM of M1 macrophages reduce ECM 
deposition by fibroblasts. 
HDFs stimulated with CM of M1 macrophages followed by stimulation with 
CM of M2 macrophages or non-CM (switch)
In wound healing, the inflammatory phase is normally followed by 
the healing phase. In both phases macrophages and fibroblasts play an 
important role. In vitro, it is shown that macrophages can be re-polarized 
from M1 to M2 and vice versa [26,27]. In vivo, there are indications that 
re-polarization of macrophages also occurs [28,29]. Therefore we investigated 
the influence of CM of M1 macrophages on fibroblasts followed by 
stimulation with CM of M2 macrophages or non-CM at 72 h (24 h CM 
M1 followed by 48 h CM M2 or non-CM) and 144 h (48 h CM M1 
followed by 96 h CM M2 or non-CM).
As shown in Figure 3, fibroblasts became pro-inflammatory after 
stimulation with CM of M1 macrophages. Figure 8A shows that if this 
stimulation is followed by CM of M2 macrophages or non-CM, the 
fibroblasts completely downregulated the gene expression of CCL2 and 
134
Chapter 5
IL6 both after 72 h and 144 h. The gene expression level of CCL2 and IL6 
was similar to fibroblasts stimulated with only CM of M2 macrophages at 
both time points.
As shown in Figure 4, expression levels of MMP1, MMP2 and MMP14 
were upregulated after stimulation of CM from M1 macrophages. 
Fibroblasts which were stimulated with CM of M1 followed by CM of M2 
macrophages or non-CM, showed a downregulation in the gene expression 
of MMP1 after 72 h and 144 h (Figure 8B). MMP2 expression by fibroblasts 
after the CM switch showed a slight decrease after 72 h. After 144 h, 
no differences in MMP2 expression levels were seen between fibroblasts 
stimulated with CM of M1 or M2 macrophages nor the switch (data not 
shown). MMP14 gene expression was downregulated in fibroblasts that 
were stimulated with CM of M1 followed by CM of M2 macrophages or 
non-CM compared to stimulation with CM of M1 macrophages after 72 
h. Similar to the gene expression of MMP2, no differences in MMP14 
expression were seen between the conditions after 144 h (data not shown). 
As shown in Figure 4A, TIMP1 was upregulated in fibroblasts after 
stimulation with CM of M1 macrophages. Fibroblasts, stimulated with 
CM of M1 followed by CM of M2 macrophages or non-CM, showed a 
TIMP1 gene expression that remained high at 72 h and 144 h, which was 
significantly different compared to fibroblasts stimulated with CM of M2 
macrophages alone (Figure 8B), indicating that CM of M2 macrophages 
nor non-CM was not able to suppress the induction of TIMP expression 
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ACTA2 gene expression was similar between fibroblasts stimulated 
with CM of M1 or M2 macrophages or the switch after 72 h. After 144 h 
fibroblasts stimulated with CM of M2 macrophages or the switch showed 
higher expression of ACTA2 compared to fibroblasts stimulated with only 
CM of M1 macrophages (data not shown). No differences were seen in 
TAGLN gene expression between the three conditions (data not shown).
COL1A1 gene expression was upregulated after the switch of CM 
compared to fibroblasts stimulated with M1 macrophages CM at 144 h 
(Figure 8C). This gene expression was similar to fibroblasts stimulated with 
CM of M2 macrophages after 144 h. No differences in COL3A1 gene 
expression were seen after the switch compared to fibroblasts stimulated 
with M1 or M2 CM in time.
The results indicate that the effects of factors produced by M1 
macrophages on HDFs diminish once HFDs are not exposed to these 
factors anymore (i.e. if HDFs are exposed to M2-CM or non-CM).
Discussion
Macrophages play important roles in wound repair processes. 
Macrophages are phenotypically highly plastic, and their polarization 
state depends on the micro-environment present in the wounded area. 
The M1 and M2 polarization states are opposite activation states of a 
continuum. Protocols to induce M1 and M2 macrophages in vitro are 
widely used, but it should be realized that the macrophage phenotype 
in wounds likely exhibit a more complex phenotype in (certain stages 
of ) wound healing [37-39]. Nevertheless, since M1 and M2 macrophages 
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are well-defined extremes, they offer interesting opportunities to study 
processes encountered during wound healing.
In this study we investigated the influence of secreted factors (conditioned 
medium) of M1 or M2 macrophages on dermal fibroblasts. Simultaneous-
ly, the influence of secreted factors of M1 macrophages followed by 
stimulation with secreted factors of M2 macrophages was investigated. In 
addition, we used conditioned medium from unstimulated macrophages. 
These unstimulated macrophages have a “M2-like” phenotype, which 
is probably caused by stimulating monocytes with macrophage 
colony-stimulating factor (M-CSF), a step that is necessary to induce 
differentiation of monocytes towards macrophages [40,41]. Despite this, the 
obtained macrophages changed their polarization status quickly when 
stimulated with LPS/IFNG or IL4/IL13 towards M1 or M2 macrophages, 
respectively. Secreted factors of these three types of macrophages influenced 
fibroblasts morphology and phenotype considerably.
In general, macrophages that invade the tissue in the inflammatory 
phase of wound healing adopt a M1 phenotype. In our model, the 
secreted factors from M1 macrophages influences the properties of 
dermal fibroblasts already within 24 h, changing the phenotype into a 
pro-inflammatory state. This indicates that fibroblasts, under the direction 
of paracrine signals of M1 macrophages, contribute to a pro-inflammatory 
environment by secreting cytokines and chemokines (such as CCL2, 
CCL7 and IL6) in the inflammatory phase of wound healing. This is in 
accordance with data shown by Holt et al.[34]. These authors showed, in 
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produce pro-inflammatory cytokines and chemokines after stimulation 
with conditioned medium of LPS-stimulated macrophages and in a 
co-culture system with direct cell-cell contact. Other studies [30,32,33] 
showed that after direct contact between macrophages and fibroblasts, 
without paying attention to the M1/M2 status of macrophages, fibroblasts 
upregulated the inflammatory proteins CCL2 and CCL3, which is in 
accordance to our results from fibroblasts stimulated with secreted factors 
from M1 macrophages.
MMPs are capable of regulating chemokine activity and ECM 
degradation in tissue repair [42,43]. MMPs are important as they support 
cellular influxes, but an excess of MMPs will damage the tissue architecture 
and a high TIMP/MMP ratio is often seen in non-healing tissues. In 
the inflammation phase of tissue repair MMPs are upregulated and the 
moment fibroblasts deposit new ECM the MMPs levels decline. In our 
model we showed that different MMPs (MMP1, MMP2, MMP3 and 
MMP14) were highly upregulated in fibroblasts that were exposed to 
paracrine factors derived from M1 macrophages. Because of the secreted 
MMPs and the pro-inflammatory state of fibroblasts after M1 stimulation, 
it is likely that in vivo the fibroblasts are able to prolong the inflammation 
state in wound healing by itself or by attracting more pro-inflammatory 
cells.
Fibroblasts exposed to conditioned medium from M2 macrophages 
showed little response. Only a slight increase was seen in the expression of 
ACTA2, but this did not resulted in myofibroblast formation. Furthermore, 




In wound repair it is thought that M2 macrophages are responsible 
for reversing the inflammatory response, thereby initiating the healing 
process. Interestingly, in this study we show that fibroblasts with an 
inflammatory phenotype (initiated by stimulation with secreted factors 
of M1 macrophages) can be reversed to an anti-inflammatory phenotype 
with secreted factors of M2 macrophages or non-CM. In these fibroblasts, 
the previously upregulated pro-inflammatory cytokines, chemokines, and 
MMPs were completely downregulated after stimulation with paracrine 
signals from M2 macrophages or non-CM. Thus, although paracrine 
factors of M2 macrophages have relatively little effect on unstimulated 
fibroblasts, they can have a major effect on fibroblasts with an inflammatory 
phenotype.
Conclusions
In summary, we have shown that secreted factors from M1 macrophages 
gives rise to fibroblasts with a pro-inflammatory and ECM-degrading 
profile, while M2 macrophages induce fibroblast proliferation. The 
pro-inflammatory and ECM-degrading fibroblast can be reversed 
completely by secreted factors from M2 macrophages or non-CM. 
Therefore, not only macrophages, but also fibroblasts show a high dynamic 
plasticity in wound healing / tissue repair processes, a plasticity that seems 
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The hallmark of fibrosis is an accumulation of fibrillar collagens, 
especially of collagen type I. There is considerable debate whether in vivo 
type II epithelial-to-mesenchymal transition (EMT) is involved in organ 
fibrosis. Lineage tracing experiments by various groups show opposing 
data concerning the relative contribution of epithelial cells to the pool of 
myofibroblasts. We hypothesized that EMT-derived cells might directly 
contribute to collagen deposition. To study this, EMT was induced in 
human epithelial lung and renal cell lines in vitro by means of TGF-β1 
stimulation, and we compared the collagen type I (COL1A1) expression 
levels of transdifferentiated cells with that of myofibroblasts obtained by 
TGF-β1 stimulation of human dermal and lung fibroblasts. COL1A1 
expression levels of transdifferentiated epithelial cells appeared to be at least 
one to two orders of magnitude lower than that of myofibroblasts. This was 
confirmed at immunohistochemical level: in contrast to myofibroblasts, 
collagen type I deposition by EMT-derived cells was not or hardly 
detectable. We postulate that, even when type II EMT occurs in vivo, 
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Introduction 
In adults, the endpoint of wound repair is often an excessive accumulation 
of fibrillar collagen, also known as fibrosis or scar formation. Tissue or 
organ scarring is a leading cause of morbidity and mortality, and it is 
estimated that 45% of deaths in the U.S.A. can be attributed to fibrosing 
disorders [1]. Due to its prominence in chronic diseases, fibrosis represents 
an enormous health burden. So far, there are no specific therapeutic agents 
available to treat scarring, i.e. to attenuate the pathological accumulation 
of collagen.
The cells that are responsible for the deposition of collagen are fibroblasts 
and especially myofibroblasts [2-5]. There is remarkably little consensus about 
the origin of these myofibroblasts. Several cell sources have been identified, 
such as local fibroblasts, bone marrow-derived fibrocytes, endothelial cells, 
epithelial cells, and macrophages [6-8]. The relative contribution of these cell 
sources to the pool of myofibroblasts in fibrotic tissues is largely unknown, 
and might even vary from organ to organ or from the pathology involved. 
In addition, and more importantly, no report has been published that has 
quantified collagen deposition in fibrosis as a function of myofibroblast 
origin.
During the last decade, considerable attention has been given to the 
role of the so-called type II epithelial-to-mesenchymal transition (EMT) 
in fibrosis. It has been postulated that epithelial cells can be converted 
in vivo into mesenchymal cells with a fibroblast-like phenotype. Type II 
EMT has been reported for various organs, such as the kidney [9, 10], the 
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lung [11-13], and the liver [14, 15]. Whether EMT occurs during fibrogenesis in 
vivo is currently under debate [16-21]). According to several lineage tracing 
studies in vivo, over 30% of the fibroblasts are derived from epithelial 
cells by means of EMT [9, 10, 13, 15]. However, other (lineage tracing) in vivo 
experiments did not reveal evidence that EMT contributes significantly to 
the fibroblast pool [22-30]. These conflicting data makes it difficult to design 
rational treatments aimed at attenuating fibrotic processes.
In this paper, we have approached the question whether EMT 
contributes to organ fibrosis from a different angle. It has been shown that 
EMT can be induced in vitro: the addition of transforming growth factor 
beta1 (TGF-β1) to cultured epithelial cells quickly leads to the emergence 
of cells with mesenchymal characteristics [31-33]. However, there are no in 
vitro studies showing comparative data of collagen expression or deposition 
between fibroblast-like cells derived from EMT and myofibroblasts 
derived from interstitial fibroblasts. Therefore, it is not known whether 
e.g. a myofibroblast derived from an epithelial cell deposits less or more 
collagen compared to a myofibroblast derived from a local fibroblast.
In this study, we used TGF-β1 to induce (a) transdifferentiation 
of epithelial cell lines from two different organs (kidney and lung) and 
(b) activation of fibroblasts (dermis and lung) into myofibroblasts. We 
compared collagen type I and III expression levels of EMT-derived cells 
with the expression levels of (myo)fibroblasts, and show that EMT-derived 
cells most likely do not contribute significantly to collagen deposition in 
fibrosis. It is reasonable to assume that, even when EMT occurs during 








The human proximal renal tubule epithelial cell line (HK-2; ATCC, 
Manassas, USA) was cultured in DMEM-F12 medium (Invitrogen, Breda, 
The Netherlands), supplemented with 1% penicillin, 1% streptomycin 
(10.000 U/ml, Gibco, Paisley, UK), 10 ng/ml epithelial growth factor 
(Peprotech, Rocky Hill, USA), 10 µg/ml insulin, 5.5 µg/ml transferrin, 
6.7 ng/ml sodium selenite (Cambrex, East Rutherford, USA), 36 ng/ml 
hydrocortisone (Sigma-Aldrich, Zwijndrecht, The Netherlands), 2 mM 
Glutamax (Invitrogen) and 10% fetal calf serum (FCS; Perbio Science, 
Etten-Leur, The Netherlands). HK-2 cells were cultured at 37 °C in a 
humidified atmosphere at 5% CO2.
Conditionally immortalized human proximal tubular cells (ciPTEC; [34]) 
were cultured in DMEM-F12 medium supplemented with 5 µg/ml insulin, 
5 µg/ml transferrin, 5 ng/ml selenium, 36 ng/ml hydrocortisone, 10 ng/ml 
epithelial growth factor, 40 pg/ml trio-iodothyronine (Sigma-Aldrich) and 
10% FCS at 33 °C in a humidified atmosphere at 5% CO2. Preliminary to 
experiments, ciPTEC were cultured for 7 days at 37 °C, allowing the cells 
to mature to their proximal tubule phenotype.
The human bronchial epithelial cell line (BEAS-2B; ATCC) was cultured 
in RPMI 1640 medium (Lonza, Breda, The Netherlands) supplemented 
with 1% penicillin, 1% streptomycin, 2 mM L-glutamine (Lonza) 
and 10% FCS. BEAS-2B cells were cultured at 37 °C in a humidified 
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atmosphere at 5% CO2.
Primary human adult dermal (HDF) and lung (HLF) fibroblasts (both 
ATCC) were cultured in EMEM medium (Lonza) supplemented with 1% 
penicillin, 1% streptomycin, 2 mM L-glutamine (Lonza) and 10% FCS. 
Fibroblasts were cultured at 37 °C in a humidified atmosphere at 5% CO2.
Stimulation of cells with TGF-β1
Cells were seeded at a concentration of 15.000/cm2 in 6 wells plates 
(Corning B.V. Life Sciences, Amsterdam, The Netherlands) in medium 
containing 10% FCS. After 24 hours the medium was removed and 
replaced with medium containing 0.5% FCS and 50 ng/ml L-ascorbic acid 
2-phosphate sesquimagnesium salt hydrate (vitamin C, Sigma-Aldrich) 
overnight. Subsequently, cells were exposed with or without 10 ng/ml 
recombinant TGF-β1 (Peprotech) for 1 and 7 days, with daily medium 
replacements. 
Quantitative RT-PCR (qRT-PCR)
Total RNA from TGF-β1-stimulated and unstimulated cells was 
isolated using the RNeasy Mini Kit (Qiagen, CA, USA) according to the 
manufacturer’s protocol. Next, total RNA was reverse-transcribed using 
the FirstStrandcDNA synthesis kit (Fermentas, St. Leon-Rot, Germany) 
according to the manufacturer’s instructions. Quantification of gene 
expression by qPCR was performed in a final reaction volume of 10 µl, 
consisting of 1× SYBR Green Supermix (Bio-Rad, Hercules, USA), 6 
µM forward primer, 6 µM reverse primer (Biolegio B.V., Nijmegen, The 
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95 °C for 15 s, 60 °C for 30 s, 72 °C for 30 s, for 40 cycles in a ViiATM7 
Real-Time PCR System (Applied Biosystems, CA, USA). Data analysis 
was performed using ViiATM7 Real-Time PCR System Software v1.1 
(Applied Biosystems).
Immunofluorescence stainings
After 1 and 7 days of culture on Permanox chamberslides (Nunc, 
New York, USA), cells were washed twice with PBS and fixed in 2% 
paraformaldehyde (Merck, Darmstadt, Germany) at room temperature 
for 10 minutes. Fixed cells were incubated with (1) mouse anti-human 
alpha actin-2 (1:100; ACTA2; Dako (M0851), Glosstrup, Denmark), 
(2) goat anti-human vimentin (1:50; Santa Cruz Biotechnology (C-20), 
Santa Cruz, USA), (3) EPCAM (undiluted; MOC31 hybridoma 
culture supernatant) or (4) mouse anti-human collagen I (1:100; Abcam 
(ab90395), Cambridge, UK) diluted in PBS containing 1% bovine serum 





























albumin (BSA; Sanquin, Amsterdam, The Netherlands) for 1 h at room 
temperature. After three washes with PBS, cells were incubated with 
biotinylated (1) goat anti-mouse IgG2a (1:100), (2) rabbit anti-goat IgG 
(1:50) or (3,4) goat anti-mouse IgG1 (1:100) (all three; SouthernBiotech, 
Alabama, USA) diluted in 2% normal human serum (NHS)/PBS for 30 
min at room temperature. Then the cells were washed three times with 
PBS and incubated with streptavidine-CY3 (1:400; Dako) in PBS/DAPI 
(1:5000) for 30 min. After three washes with PBS slides were mounted 
in Citifluor (Agar Scientific, Stansted, UK) and visualized using a Leica 
DMRA Immunofluorescent microscope and Leica software (Leica 
Microsystems, Rijswijk, The Netherlands).
Statistical analysis
All data are represented as means ± standard error of the mean of 
three independent experiments and were analyzed by two-way ANOVA 
followed by Tukey’s post hoc analysis using GraphPad Prism Version 5 
(GraphPad Software, La Jolla, USA). Values of p<0.05 were considered to 
be statistically significant. 
Results 
TGF-β1 induces EMT in HK-2, ciPTEC and BEAS-2B cell lines
In control medium, human renal proximal tubule epithelial cells 
(HK-2) showed a cobblestone epithelial-specific morphology (Fig. 1A). 
Upon stimulation with TGF-β1 for 1 day, the epithelial monolayer 
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mesenchymal phenotype was more pronounced after 7 days of TGF-β1 
stimulation (Fig. 1A).
Conditionally immortalized human proximal tubule cells (ciPTEC) 
showed a more heterogeneous morphology in control medium, although 
most of the cells had a cobblestone morphology (Fig. 1A). Upon TGF-β1 
stimulation, cells adopted a mesenchymal phenotype after 1 day. After 7 
days of stimulation, cell clusters were formed composed of cells with a 
spindle-shaped morphology (Fig. 1A).
Human lung bronchial epithelial cells (BEAS-2B) showed an 
epithelial-like morphology after 1 day in control medium as well as in 
medium containing TGF-β1 (Fig. 1A). After 7 days of TGF-β1 stimulation, 
the cells adopted a spindle-shaped morphology (Fig.1A).
EMT of these three epithelial cell lines was further confirmed by analysis 
of gene and protein expression levels (Fig. 1B-D). HK-2 cells downregulated 
the expression of the epithelial-specific genes epithelial cell adhesion 
molecule (EPCAM) and E-cadherin (CDH1) after TGF-β1 treatment for 
1 and 7 days (Fig. 1B). EPCAM downregulation was confirmed at protein 
level (Fig. 1C). Expression of the mesenchymal marker vimentin (VIM) 
was upregulated after TGF- β1 stimulation at both time points (Fig. 1B), 
which was confirmed at protein level (Fig. 1D). Another mesenchymal 
marker associated with EMT, smooth muscle protein 22-alpha (TAGLN), 
was upregulated after 1 day of TGF-β1 stimulation in HK-2 cells (Fig. 
1B). 
ciPTEC cells showed a decreased expression of EPCAM and 
CDH1 after 7 days of TGF-β1 stimulation (Fig. 1B). EPCAM could 
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Figure1. Induction of EMT in HK-2, ciPTEC and BEAS-2B cells. (A) Morphology of unstimulat-
ed HK-2 cells, ciPTEC cells, BEAS-2B cells and cells stimulated with 10ng/ml TGF-β1  after 1 and 
7 days of culture. Original magnification 100x. (B) qRT-PCR on control and TGF-β1 stimulated 
epithelial cells. Epithelial markers EPCAM and CDH1 are downregulated and mesenchymal 
markers VIM and TAGLN are upregulated after TGF-β1 stimulation. (C) EPCAM staining on 
control and TGF-β1 treated epithelial cells (original magnification 100x). (D) Vimentin staining 
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not be detected at protein level (Fig. 1C). VIM expression showed no 
differences between unstimulated and stimulated cells, although a trend 
of upregulation is observed after TGF-β1 stimulation (Fig. 1B), which 
was confirmed at protein level (Fig. 1D). TAGLN was upregulated upon 
TGF-β1 stimulation at both time points (Fig. 1B).
BEAS-2B cells stimulated with TGF-β1 did not show any differences 
in EPCAM expression (Fig. 1B). The gene expression level of EPCAM 
was already very low compared to that of HK-2 or ciPTEC. Indeed, no 
EPCAM could be detected on protein level (Fig. 1C). VIM expression 
levels also did not show differences compared to unstimulated cells (Fig. 
1B), although VIM showed a more intense staining on protein level 
after TGF-β1 stimulation (Fig. 1D). CDH1 was downregulated after 7 
days of TGF-β1 stimulation and TAGLN was upregulated after 1 day of 
stimulation (Fig. 1B). Expression levels of myofibroblast marker alpha 
smooth muscle actin (ACTA2) remained very low in all three epithelial cell 
lines (data not shown), even after TGF-β1 stimulation. ACTA2 protein 
levels could not be detected.
Overall these results confirm that epithelial cells derived from kidney 
(HK-2 and ciPTEC) and lung (BEAS-2B) clearly undergo EMT after 
TGF-β1 stimulation and that these models can be used to study their 
contribution in collagen deposition during EMT in vitro.
TGF-β1 induces myofibroblast differentiation in adult dermal and lung 
fibroblasts
Human adult dermal fibroblasts (HDF) showed a classic fibroblast 
phenotype in control medium. After 7 days of stimulation with TGF-β1, 
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the cells became more stretched (Fig. 2A). These morphological changes 
were accompanied by changes in gene expression and on protein level (Fig. 
2B-D). HDF upregulated the myofibroblast marker ACTA2 after 7 days 
of TGF-β1 stimulation (Fig. 2B), which was confirmed at protein level 
(Fig. 2C). In untreated cells, the basal expression level of VIM was already 
high. There was a small decrease in VIM expression after 7 days of TGF-β1 
treatment compared to untreated cells (Fig. 2B). At protein level, no clear 
differences of VIM were detected between stimulated and unstimulated 
cells (Fig. 2D).
Human adult lung fibroblasts (HLF) showed a more elongated 
morphology in control medium compared to HDF (Fig. 2A and Fig. 
2E). After TGF-β1 stimulation, no morphological changes occurred. 
However, there was an >8 fold upregulation of ACTA2 already after 1 day 
of TGF-β1 stimulation, with an increased expression over time (Fig. 2F). 
At protein level, only a difference in ACTA2 staining was seen after 7 days 
of stimulation (Fig.2G). No differences were found in VIM expression 
(Fig. 2F) or on protein level (more cells were present in TGF-β1 treated 
cultures, all cells were positive for vimentin) (Fig. 2H).
These results indicate that dermal and lung fibroblasts are activated by 
TGF-β1 leading to differentiation into myofibroblasts.
Comparison of collagen type I gene expression and protein levels between 
epithelial cells and fibroblasts
In addition to the contractile character (displayed by the expression 
of genes involved in cytoskeletal organization) of mesenchymal cells, 
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Figure2. Myofibroblast differentiation of human dermal and lung fibroblasts. (A) Morphology 
of unstimulated dermal fibroblasts and dermal fibroblasts stimulated with 10ng/ml TGF-β1  after 
1 and 7 days of culture. Original magnification 100x. (B) qRT-PCR on control and TGF-β1 
stimulated dermal fibroblasts. Myofibroblast marker ACTA2 is significantly upregulated after 7 
days of TGF-β1 simulation. (C) ACTA2 staining and (D) vimentin staining on dermal fibroblasts. 
E) Morphology of unstimulated lung fibroblasts and lung fibroblasts stimulated with 10ng/ml 
TGF-β1  after 1 and 7 days of culture. Original magnification 100x. F) qRT-PCR on control 
and TGF-β1 stimulated lung fibroblasts. ACTA2 is significantly upregulated after 1 and 7 days of 
TGF-β1 simulation. (G) ACTA2 and (H) vimentin staining on lung fibroblasts (original magnifica-
tion 100x). *p < 0.05, ***p < 0.001.
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and type III, is another characteristic of mesenchymal cells, that plays an 
important role in fibrosis.
Transcription of collagen type I (COL1A1) was strongly upregulated 
after induction of EMT in all three epithelial cell lines (Fig. 3A). HK-2 cells 
and BEAS-2B cells showed a >45 fold upregulation after 7 days of TGF-β1 
Figure3. Collagen type I expression and deposition in absence and presence of TGF-β1. (A) 
qRT-PCR on HK-2, ciPTEC, BEAS-2B, HDF and HLF for COL1A1. **p < 0.01, ***p < 0.001. 
(B) Comparison of COL1A1 gene expression levels between HK-2, ciPTEC, BEAS-2B, HDF 
and HLF. ^^p<0.01; different compared to HK-2, ^^^p<0.001, ##p<0.01; different compared 
to ciPTEC,  ###p<0.001, ‡‡p<0.01; different compared to BEAS-2B, ‡‡‡p<0.001, $$$p<0.001; 
different compared to HDF.  (C) COL1A1 protein staining on TGF-β1 treated HK-2, ciPTEC, 




Epithelial to mesenchymal transition
stimulation and ciPTEC cells a >15 fold upregulation. HDFs showed a 
more moderate upregulation of COL1A1 after TGF-β1 stimulation 
(<3-fold), whereas HLFs did not show any differences between stimulated 
and unstimulated cells.
Although COL1A1 could be upregulated by TGF-β1 in HK-2 and 
ciPTEC, gene expression of COL1A1 was > 100-fold lower compared 
to that of myofibroblasts derived from HLF and HDF. BEAS-2B also 
showed markedly lower levels (about 10-fold) of COL1A1 compared to 
these myofibroblasts (Fig. 3B). There was a significantly higher COL1A1 
expression present after TGF-β1 stimulation in HDF compared to HLF 
at both time points (Fig. 3B). Deposited protein levels of collagen type I 
were determined after 7 days of culture under the influence of TGF-β1. 
Myofibroblasts derived from HDF and HLF showed a much higher 
collagen I deposition compared to all three transdifferentiated epithelial 
cell lines (Fig. 3C).
These results indicate that collagen type I expression and deposition by 
mesenchymal cells derived from EMT is one to two orders of magnitude 
lower compared to dermal and lung-derived myofibroblasts.
Comparison of collagen type III gene expression levels between epithelial cells 
and fibroblasts
In addition to collagen type I, gene expression levels of collagen type 
III (COL3A1) were examined. After 7 days of TGF-β1 stimulation, 
epithelial cells showed an upregulation of COL3A1 (Fig. 4A), although 
the only significant difference was observed between unstimulated 
and stimulated HK-2 cells. HDF showed an upregulation of COL3A1 
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after 1 day of TGF-β1 stimulation and a downregulation after 7 days 
of stimulation compared to unstimulated cells (Fig. 4A). HLF also 
showed a downregulation of COL3A1 after 7 days of stimulation, but 
no upregulation after 1 day of TGF-β1 stimulation (Fig. 4A). Expression 
levels of COL3A1 of EMT-induced epithelial cells was negligible (>225 
fold lower) compared to the expression levels of both myofibroblast types 
(Fig. 4B).
These results indicate that the collagen type III expression by 
epithelium-derived mesenchymal cells is orders of magnitude lower 
compared to lung or dermal myofibroblasts. 
Figure4. Collagen type III expression in absence and presence of TGF-β1. (A) qRT-PCR on 
HK-2, ciPTEC, BEAS-2B, HDF and HLF for COL3A1. (B) Comparison of COL3A1 gene 




During the last decade, several research groups provided support for 
the possibility that EMT occurs during organ fibrosis [9, 11-13]. This concept 
has recently been challenged, based on the results of e.g. new fate-mapping 
experiments, suggesting that (myo)fibroblasts are exclusively derived from 
sources other than epithelial cells [22-24]. These studies focused mainly on 
the question whether EMT-derived mesenchymal cells play a role in the 
accumulation of myofibroblasts during fibrosis. However, little is known 
about whether myofibroblasts derived from EMT contribute to ECM 
deposition, the hallmark of fibrosis. It is known that myofibroblasts derived 
from fibroblasts are able to produce an excessive amount of ECM during 
fibrosis. In this study, we investigated the expression levels of collagen 
type I and type III by EMT-derived mesenchymal cells. In addition, we 
compared these to the levels produced by myofiboblasts to predict the 
contribution of ECM deposition by transdifferentiated epithelial cells.
In our model, we stimulated epithelial cells and fibroblasts with TGF-β1 
for up to 7 days. By doing so, kidney and lung epithelial cells lost their 
cobblestone morphology and adopted an elongated spindle-like shape. 
Transdifferentiation of epithelial cells into mesenchymal cells was further 
confirmed by downregulation of epithelial markers (EPCAM and CDH1) 
and upregulation of mesenchymal markers (VIM and TAGLN). Dermal 
and lung fibroblasts transdifferentiated into myofibroblasts under the 
influence of TGF-β1 (upregulation of α-smooth muscle actin (ACTA2) 
and increased ACTA2 protein levels). Despite the TGF-β1 mediated 
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epithelial transdifferentiation, the expression of the myofibroblast 
marker ACTA2 remained very low, and on protein level ACTA2 was not 
detected. In a recent review [16], it was suggested that the expression of 
ACTA2 should not be used as a criterion for EMT, as several in vitro 
studies showed that different types of epithelial cells treated with TGF-β1 
transdifferentiated into mesenchymal cells but showed markedly different 
responses with respect to ACTA2 expression. Normal rat kidney tubular 
epithelial cells (NRK52E) [32], human proximal tubular epithelial cells 
(HKC-8) [35] and porcine tubular epithelial cells (LLC-PK1) [33] showed 
an increased expression of ACTA2 after in vitro TGF-β1 stimulation, 
although TGF-β1stimulated primary human tubular epithelial cells did 
not show de novo ACTA2 expression [36]. 
In fibrosis, excessive collagen type I and type III deposition occurs. 
Several studies have shown an increase in COL1A1 and COL3A1 gene 
expression levels in renal [37] as well as in lung [31] epithelial cells after 
EMT induction, but did not show how these levels are in proportion 
with the levels produced by fibroblasts and myofibroblasts. In this 
study we showed that COL1A1 expression of epithelial cells was highly 
upregulated after 1 and 7 days of TGF-β1 stimulation (and to a lesser 
extent COL3A1 as well). However, these levels were still dramatically 
lower (even after 7 days of stimulation with TGF-β1) when compared to 
the levels seen in myofibroblasts. Indeed, collagen deposition by all three 
types of transdifferentiated epithelial cells (from two different organs) 
was negligible. Because all three epithelial cell lines did not show collagen 
deposition, we do not expect that primary epithelial cells would deposit 
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collagen I. In contrast to the lack of collagen deposition by transdifferenti-
ated epithelial cells, a high collagen deposition was seen in myofibroblasts 
derived from fibroblasts. This suggests that ECM deposition in organ 
fibrosis is predominantly produced by fibroblast-like cells that are not 
derived from epithelial sources: the contribution of collagen deposition by 
mesenchymal cells derived from EMT is minor. On the other hand, the 
total number of epithelial cells in the kidney is markedly higher, compared 
to the amount of fibroblasts. The significant induction of COL1A1 and 
COL3A1 induced by TGF-β1 in epithelial cells could therefore trigger the 
progression of fibrosis.
Both dermal and lung fibroblasts showed, after activation by TGF-β1, 
massive myofibroblast transformation, as revealed by immunohistochemi-
cal staining of ACTA2. However, dermal myofibroblasts showed a 
significant increase in COL1A1 expression after TGF-β1 stimulation, 
whereas no differences in COL1A1 expression were observed between 
unstimulated and stimulated lung fibroblasts. Basal levels of COL1A1 
gene expression in unstimulated dermal and lung fibroblasts were not 
different, but after TGF-β1 stimulation dermal fibroblasts showed a 
significantly higher COL1A1 expression. It thus seems that there are 
differences in the behaviour of fibroblasts derived from different tissues. 
Indeed, genome-wide expression studies demonstrate that fibroblasts from 
different tissues show major differences in phenotypical properties [38]. 
In summary, we showed that collagen type I gene expression levels 
in transdifferentiated epithelial cells derived from two different organs 
(kidney and lung) were dramatically lower compared to the levels found in 
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dermal and lung myofibroblasts. This was substantiated by protein levels, 
suggesting that the contribution to ECM deposition in organ fibrosis by 
cells from the epithelium is negligible.
Conclusions 
In this study we used TGF-β1 to induce (a) transdifferentiation of 
epithelial cell lines from two different organs (kidney and lung) and 
(b) activation of fibroblasts (dermis and lung) into myofibroblasts. We 
compared, amongst others, collagen type I and III expression levels of 
EMT-derived cells with the expression levels of (myo)fibroblasts, and 
show that collagen expression by mesenchymal cells derived from EMT 
is at least one to two orders of magnitude lower compared to dermal and 
lung-derived myofibroblasts. As this was also observed on protein level, 
we conclude that, even when EMT occurs during fibrogenesis in vivo, it is 
not likely that the resulting cells contribute significantly to the hallmark of 
fibrosis, namely an excessive accumulation of fibrillar collagen deposition. 
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Rationale for in utero repair of spina bifida
Spina bifida is a congenital closure defect of the neural tube that 
occurs in approximately 1 of every 2,000 live births. Spina bifida can 
lead to hydrocephalus, mental impairment, paraplegia, urinary and fecal 
incontinence, sexual dysfunction and skeletal deformities. The neural 
damage in spina bifida is caused by two hits; the ‘first’ hit is the failure of the 
neural tube to close and the ‘second’ hit is the exposure of the neural tissue 
to the amniotic fluid during pregnancy. The rationale for fetal therapy is 
to prevent this second hit, eventually leading to less neural damage. In the 
USA, a randomized trial (the MOMs trial) [1] has been performed. In this 
trial two treatment methods were used; postnatal surgery and fetal surgery, 
showing a better neural outcome for patients that were treated in utero, 
but fetal surgery was also associated with higher rates of preterm birth. 
Importantly, this clinical trial demonstrated that there is an improvement 
of neural function after fetal repair (e.g. less shunting is needed) but it is 
also clear that new strategies need to be developed to improve fetal therapy 
for spina bifida patients. A promising approach might be the use of tissue 
engineering. A tissue engineered construct may also make endoscopic 
treatment possible. Compared to open surgery, endoscopic treatment is less 
invasive for the mother and might lead to lower rates of premature birth. 
In this thesis, we studied different tissue engineering techniques including 
growth factor loaded scaffolds and the possibility of using amniotic fluid 





Tissue engineering for in utero repair of spina bifida  
It has previously been shown that collagen type I scaffolds can be used 
to close a spina bifida defect in a fetal sheep model [2-4], thereby preventing 
severe damage to the spinal cord, leading to a better neurological outcome 
compared to untreated lambs. However, in these studies, wound healing 
was not optimal. It is highly important that wound contraction and scar 
formation will be minimized after fetal skin defects, as the fetus grows 
rapidly. To improve wound healing, we investigated the effect of the 
addition of two growth factors, basic fibroblast growth factor (FGF-2) and 
vascular endothelial growth factor (VEGF), to a collagen type I scaffold 
in a fetal sheep skin defect model (Chapter 2). Compared to defects 
that are treated with bare collagen type I scaffolds, skin defects treated 
with growth factor loaded scaffolds showed enhanced epidermialization 
and vascularization and less wound contraction. Furthermore, new skin 
appendages were formed in the wounded area of the growth factor treated 
wounds 8 weeks after surgery. These results indicate that the addition of 
growth factors FGF-2 and VEGF to a collagen type I scaffold improves 
fetal skin wound healing. Future studies need to be performed with these 
scaffolds in a spina bifida sheep model to see whether this construct is 
suitable for spina bifida treatment. The remodeling and degradation of the 
scaffold in the growth factor-treated wounds in the fetal skin model was 
still in progress at 8 weeks post surgery, therefore it is important to include 
later time points in future studies. Furthermore, the optimal loading 
concentration of the growth factors needs to be established.  
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The use of amniotic fluid cells for fetal therapy to treat spina bifida
Another option to improve wound healing can be the addition of 
stem cells to a scaffold. The amniotic fluid is an attractive cell source for 
fetal therapy.  In Chapter 3 we studied the possibility of using amniotic 
fluid-derived cells for skin tissue engineering. For this we generated a 
dermo-epidermal skin graft containing human primary amniotic fluid 
cells (AFCs) in the dermis and compared it with a graft containing human 
fibroblasts in the dermis. We found that 21 days after transplantation into 
immuno-incompetent rats of the grafts containing amniotic fluid cells, 
these cells correctly support epidermal survival and stratification, meaning 
that these cells can efficiently substitute fibroblasts. As in this study we 
used adult rats, it would be interesting to use a fetal sheep skin defect 
model to investigate the fetal response to such a construct containing 
amniotic fluid cells.
The advantage of using amniotic fluid cells for fetal therapy is that in 
theory, cells can be isolated early during pregnancy and that the same cells 
after expansion in vitro can be placed in a tissue-engineered construct and 
transplanted onto the defect in the fetal period, hereby using autologous 
cells. Although there are many studies investigating the potential of healthy 
AFCs, no studies have been performed with human AFCs from fetuses with 
a neural tube defect (NTD). In Chapter 4 we studied collagen I deposition 
by healthy AFCs and NTD-AFCs, as extracellular matrix deposition is an 
important aspect in tissue engineering for spina bifida. TGF-β1 stimulated 
healthy AFCs and primary fetal fibroblasts deposited collagen type I in 





type I. Furthermore, NTD-AFCs had lower mRNA expression levels of 
several genes involved in collagen biosynthesis compared to both healthy 
AFCs and fetal fibroblasts, indicating that NTD-AFCs have different 
characteristics compared to healthy AFCs. The reason why these cells are 
so different is still a mystery, as the function of these cells in the amniotic 
fluid is unknown. Another study has also shown that there are differences 
between healthy amniotic fluid and NTD amniotic fluid in a rat spina 
bifida model [5]. That study found neural stem cells present in amniotic 
fluid from NTD fetuses but not in amniotic fluid from healthy fetuses. 
Altogether, this illustrates that more research has to be carried  out before 
NTD-AFCs can be used into a clinical setting, if possible at all. 
Based on Chapters 3 and 4 we suggest that healthy human AFCs 
might be suitable for skin tissue engineering while NTD-AFCs are not. 
AFSCs are known to have immunomodulatory characteristics which make 
them attractive cell candidates for allogeneic therapy. Several studies have 
reported that AFCs express human leukocyte antigen (HLA)-ABC (MHC 
class I) but not HLA-DR (MHC class II) [6-9] and that AFCs are able to 
inhibit T-cell proliferation in vitro [10;11]. In addition to the immunosuppres-
sive properties of AFCs that are used in the tissue engineered construct 
in the setting of fetal therapy, the fetus that receives the graft has an 
immature immune system, which might be less susceptible to immune 
rejection. Despite these properties, in vivo studies with allogeneic stem 
cell therapy have not been successful yet. A fetal sheep model of tracheal 
repair demonstrated that tissue-engineered cartilage derived from amniotic 
fluid cells enabled newborn lambs to have a functional airway; however 
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this construct only lasted for 10 days after birth. Because these tracheal 
constructs were not derived from autologous amniotic fluid cells, they were 
prone to immunologic rejection. In addition, the only clinically successful 
in utero allogeneic stem cell therapy using hematopoietic stem cells has been 
carried out in severely immunologically compromised fetuses, suggesting 
that the fetal immune system does play an important role in the success of 
in utero stem cell therapy [12]. Future in vivo studies with human amniotic 
fluid cells should be performed to investigate if NTD-AFCs can be used 
for skin tissue engineering. 
Paracrine signaling between fibroblasts and macrophages in adult wound 
repair
Fibroblasts and macrophages are two cell types that play an important 
role in wound healing. In Chapter 5 we investigated the effect of factors 
secreted by classically activated (M1) and alternatively activated (M2) 
macrophages on human adult dermal fibroblasts. It is thought that M1 
macrophages play a role in the inflammatory phase of wound healing, while 
M2 macrophages are involved in the remodeling phase. We found that 
adult fibroblasts stimulated with conditioned medium of M1 macrophages 
secreted pro-inflammatory cytokines and chemokines, such as CCL2, CCL7 
and IL6. In addition to the production of pro-inflammatory cytokines, 
M1-stimulated adult fibroblasts showed an upregulation of several matrix 
metalloproteinases (MMP1, MMP2, MMP3 and MMP14) and increased 
proteolytic activity. For future studies, it would be interesting to investigate 
the effect of conditioned medium from M1 and M2 macrophages on fetal 





in fetal scarless healing, react differently (compared to adult dermal 
fibroblasts) to factors produced by macrophages. Furthermore, it has been 
shown that fetal monocytes have the capacity to produce proinflammato-
ry cytokines in response to stimulation, but that they show a different 
expression pattern of these pro-inflammatory cytokines compared to adult 
monocytes [13]. Therefore, it is interesting to study the paracrine signaling 
between fetal monocytes and fetal dermal fibroblasts in fetal repair.
Role of epithelial to mesenchymal transition in organ fibrosis
Fibrosis is the result of excessive extracellular matrix deposition, 
particularly of collagen type I. The cells that are responsible for the 
deposition of collagen are mainly myofibroblasts, which can derive 
from different cell sources. There is considerable debate whether in vivo 
epithelial-to-mesenchymal transition (EMT) is involved in organ fibrosis 
[14-19]. Lineage tracing experiments by various groups show opposing 
data concerning the relative contribution of epithelial cells to the pool 
of myofibroblasts [20-32]. It is not known whether a myofibroblast derived 
from an epithelial cell deposits less or more collagen compared to a 
myofibroblast derived from a local fibroblast. In chapter 6 we describe 
an in vitro study in which we induced EMT by the addition of TGF-β1 
to kidney and lung epithelial cells and analyzed their collagen deposition 
and compared it to the deposition of myofibroblasts that are derived from 
dermal and lung fibroblasts. We found that EMT-derived cells had a 10 to 
100 fold lower expression of collagen type I compared to myofibroblasts, 
which was confirmed at protein level. This could indicate that, even when 
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EMT would occur during fibrogenesis in vivo, the EMT-derived cells have 
a minor role in collagen deposition. In our model, we used three different 
epithelial cell lines (from kidney and lung) and compared their collagen 
deposition to two types of fibroblasts (from dermis and lung); it would 
be interesting to compare collagen deposition of TGF-β1 stimulated 
primary kidney epithelial cells with primary kidney fibroblasts in a future 
experiment.
Future perspectives
In this thesis we showed that growth factor loaded scaffolds as well 
as tissue engineered constructs containing amniotic fluid derived cells are 
promising candidates for future fetal therapy for spina bifida. However, 
more research needs to be performed before these constructs can be used 
in a clinical trial. It is especially important to investigate the characteristics 
of NTD-AFCs in more detail, and constructs containing NTD-AFCs 
should be tested in an in vivo model. 
In this thesis we focused on the regeneration of skin tissue, but for spina 
bifida the repair of the neural tissue is of importance as well. In future 
studies, the constructs described in this thesis need to be tested in a spina 
bifida fetal sheep model to assess both neural outcome and functional 
wound repair. Furthermore, to place the constructs at the site of defect, 
minimal invasive techniques, such as endoscopy, need to be investigated. 
The endoscopic approach in treatment of fetal anomalies may overcome 
the problem of premature birth, which is one of the severe complications 
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Spina bifida is een aangeboren sluitingsdefect van de neurale buis en 
komt voor bij ongeveer 1 op de 2000 geboorten. Spina bifida kan leiden tot 
hydrocephalus, mentale retardatie, verlamming van het onderste gedeelte 
van het lichaam, urologische en orthopedische afwijkingen. De oorzaak 
van spina bifida is onbekend, maar waarschijnlijk spelen zowel genetische 
als omgevings factoren een rol. 
Doordat de neurale buis niet sluit tijdens de embryonale ontwikkeling, 
staat de ruggengraat bloot aan het vruchtwater. Deze blootstelling blijkt 
deels de oorzaak te zijn van de neurale schade ten gevolge van spina bifida. 
Afdekken van de open neuraal buis in een vroeg foetaal stadium zou dus 
schade kunnen beperken. 
Een klinische trial uitgevoerd in de VS heeft twee behandelingsmeth-
odes met elkaar vergeleken: postnatale sluiting van het neuraal buis defect 
en foetale sluiting van het defect. Patiënten die foetaal behandeld zijn 
lieten een betere neurale uitkomst zien, maar foetale chirurgie leidde ook 
tot een hogere kans op premature geboorte. Dus hoewel deze patiënten 
een betere neurale uitkomst hadden, is het noodzakelijk dat er nieuwe 
strategieën ontworpen worden om foetale therapie voor spina bifida te 
verbeteren. Een veelbelovende aanpak hiervoor kan tissue engineering zijn. 
Het doel van dit proefschrift was om meer inzicht te krijgen in de 
cellulaire processen die betrokken zijn bij foetale en adulte wondheling. 
De hiermee verkregen kennis kan gebruikt worden om nieuwe therapieën 
te ontwikkelen voor bijvoorbeeld spina bifida. In de hoofdstukken 2, 3 en 
4 hebben we verschillende opties onderzocht om foetale tissue engineering 
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voor de behandeling van spina bifida te verbeteren. In hoofdstuk 2 hebben 
we collageen type I matrices gebruikt om foetale huiddefecten af te dekken 
in een foetaal schaapmodel. We hebben gevonden dat collageen type I 
matrices geschikt zijn voor de behandeling van foetale huiddefecten en 
dat foetale wondheling gestimuleerd kan worden door de toevoeging van 
de groeifactoren fibroblast growth factor (FGF-2) en vascular endothelial 
growth factor (VEGF). Foetale wonden behandeld met groeifactor beladen 
matrices lieten betere epidermis formatie zien, meer bloedvatvorm-
ing en vorming van huidadnexen zien, wat duidt op minder litteken 
weefsel vorming. Hoewel de resultaten na toevoeging van groeifactoren 
veelbelovend zijn, weten we niet wat de effecten op lange termijn zullen 
zijn en wat de optimale lading van de groeifactoren is (in deze studie is de 
maximale ladingscapaciteit gebruikt). 
Een andere optie om een verbeterde wondgenezing te induceren, naast 
de toevoeging van groeifactoren, is het toevoegen van cellen aan een matrix. 
Voor foetale therapie zijn cellen uit vruchtwater een interessante optie. 
Deze cellen kunnen verschillende groeifactoren in fysiologische levels 
produceren alsook extracellulaire matrix eiwitten. In hoofdstuk 3 hebben 
we onderzocht of cellen uit vruchtwater gebruikt kunnen worden voor 
huid tissue engineering. Hiervoor hebben we huidconstructen ontwikkeld 
bestaande uit een gel met humane vruchtwatercellen en deze vergeleken 
met huidconstructen bestaande uit een gel met dermale fibroblasten in 
een rat model. De constructen met humane vruchtwatercellen lieten 
vergelijkbare epidermis formatie zien als de constructen met fibroblasten. 
Humane vruchtwatercellen kunnen dus de fibroblast functie vervangen 
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door de essentiële communicatie tussen mesenchym en epitheel te 
ondersteunen die nodig is voor epidermale stratificatie. 
Voor toekomstige therapie is het belangrijk om autologe cellen te 
gebruiken om immuunreacties te voorkomen. Het is echter niet bekend 
wat de eigenschappen zijn van vruchtwatercellen die afkomstig zijn van 
een foetus met een neuraal buis defect. In hoofdstuk 4 hebben we humane 
neuraal buis defect cellen vergeleken met humane gezonde vruchtwatercel-
len, daaruit bleek dat deze cellen zich inderdaad anders gedragen. Neuraal 
buis defect cellen deponeren in vitro geen collageen type I eiwit, terwijl 
gezonde vruchtwatercellen wel collageen type I deponeren. Omdat synthese 
van extracellulaire eiwitten een belangrijk aspect is in tissue engineering, is 
het nadelig dat neuraal buis defect cellen geen collageen type I deponeren 
en is het mogelijk dat deze cellen niet geschikt zijn voor de behandeling 
van spina bifida. 
In wondheling en tissue engineering spelen fibroblasten en macrofagen 
een belangrijke rol. In hoofdstuk 5 hebben we het effect van uitgescheiden 
factoren van klassiek geactiveerde macrofagen (M1) en alternatief 
geactiveerde (M2) macrofagen op fibroblasten onderzocht. Uit deze studie 
bleek dat wanneer adulte dermale fibroblasten gestimuleerd worden met 
geconditioneerd medium afkomstig van M1 macrofagen, deze cellen 
pro-inflammatoire cytokines en chemokines (zoals CCL2, CCL7 en IL6) 
uitscheiden. Verder lieten deze fibroblasten een opregulatie van verschillende 
matrix metalloproteinases zien en een verhoogde proteolytische activiteit. 
De formatie van nieuw gesynthetiseerde extracellulaire matrixeiwitten 
is een belangrijk aspect in tissue engineering. Overdadige productie van 
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deze eiwitten kan echter leiden tot fibrose. De cellen die verantwoordel-
ijk zijn voor collageen depositie zijn voornamelijk myofibroblasten. De 
transdifferentiatie van epitheel cellen naar mesenchymale cellen zou een rol 
kunnen spelen in fibrose. Het is niet bekend of een myofibroblast afkomstig 
van een epitheel cel meer of minder collageen deponeert in vergelijking 
met een myofibroblast afkomstig van een lokale fibroblast. In hoofdstuk 
6 hebben we een in vitro studie beschreven waarin we transdifferentia-
tie van epitheelcellen induceren door TGF-β1 toe te voegen aan nier en 
long epitheel cellen. Vervolgens hebben we de hoeveelheid collageen 
depositie geanalyseerd van deze cellen en vergeleken met de collageen 
depositie van myofibroblasten afkomstig van dermale en long fibroblasten. 
Getransdifferentieerde epitheel cellen hadden een tien tot honderdvoud 
lagere expressie van collageen type I vergeleken met myofibroblasten, wat 
op eiwitniveau bevestigd werd. Dit suggereert dat de directe bijdrage van 
het epitheel aan fibrose minimaal is.
Samengevat, hebben we in dit proefschrift laten zien dat zowel 
groeifactor beladen matrices en constructen met vruchtwatercellen een rol 
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